

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)


PCT

(10) International Publication Number  
**WO 2004/042074 A2**

- (51) International Patent Classification<sup>7</sup>: **C12Q**
- (21) International Application Number:  
PCT/US2003/035289
- (22) International Filing Date:  
4 November 2003 (04.11.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/424,030 4 November 2002 (04.11.2002) US
- (71) Applicant (for all designated States except US): **ICOGEN CORPORATION** [US/US]; 454 North 34th Street, Seattle, WA 98103 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HAGEN, Frederick S.**, [US/US]; 1315 Lexington Way East, Seattle, WA 98112 (US).
- (74) Agents: **POOR, Brian W.**, et al.; TOWNSEND and TOWNSEND and CREW, LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**  
— of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING OF A MEMBRANE BOUND PRECURSOR PROTEIN



(57) Abstract: The present invention provides methods for the screening and identification of agents from a large library of molecular structures that can alter the cleavage of a membrane protein of interest. Agents identified by the methods of the present invention that modify the cleavage of the membrane protein can be used in the treatment and prevention of diseases such as inflammation, diabetes, cancer, Alzheimer's disease, Parkinson's disease, and the like. The methods select for and identify effector agents that bind to the membrane protein of interest causing a structural change in the structure of the membrane protein in such a way that the efficiency of the cleavage of a secretase is modulated. Further, the methods are carried out in an in vivo system that provides for physiological conditions similar or identical to conditions for membrane protein processing. Agents can be selected for their ability to cause a decrease or increase the amount of secretase cleavage of the membrane protein.

WO 2004/042074 A2



**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING OF A MEMBRANE BOUND PRECURSOR PROTEIN

5

### RELATED APPLICATIONS

This application claims priority to United States Provisional Application Serial Number 60/424,030, filed November 4, 2002, incorporated herein by reference in its entirety.

10

### BACKGROUND OF THE INVENTION

Enzymatic conversion, or processing, of cell membrane proteins during transit to the membrane or at the cell surface appears to be a relatively common occurrence. For example, a number of membrane proteins of both Type I and Type II topology also occur as a circulating soluble form. These soluble forms are often derived from a membrane bound precursor protein by proteolysis. The group of enzymes involved in these processes have become known collectively as "secretases" or "sheddas".

Typically, cleavage of a membrane bound precursor protein occurs close to the extracellular membrane surface, releasing the soluble form of the protein from the cell. This secretion usually involves either a protease or a phospholipase depending on the type of membrane anchor on the protein. Examples of proteins secreted by this mechanism include angiotensin converting enzyme (ACE; Ramchandran and Sen, *Biochemistry* 34:12645-12652, 1995),  $\beta$ -amyloid precursor protein (APP; Selkoe, *Trends Cell Biol.* 8:447-453, 1998) and other  $\beta$ -amyloids, transforming growth factor- $\alpha$  (TGF- $\alpha$ ; Massague and Pandiella, *Annu. Rev. Biochem.* 62:515-541, 1993), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ; Black *et al.*, *Nature* 385:729-733, 1997), tumor necrosis factor receptor-I and -II (TNFR-I; Mullberg *et al.*, *J. Immunol.* 155:5198-5205, 1995, and TNFR-II; Porteu and Nathan, *J. Exp. Med.* 172:599-607, 1990), Fas ligand (FasL; Tanaka *et al.*, *Nature Med.* 4:31-36, 1998), Interleukin 6 receptor (IL6R; Mullberg *et al.*, *J. Immunol.* 152:4958-4968, 1994), and the like. Many of these proteins that are the product of membrane protein processing are associated with various disease states including arthritis, cancer, diabetes, hypertension, Alzheimer's disease, among others.

30

Modulation of some processing enzymes is currently being examined for therapeutic agents. In particular, molecules that modulate the activity of a secretase that

produces a processing product associated with a disease state are of great interest. For example, tumor necrosis factor- $\alpha$  converting enzyme (TACE, ADAM17, CD156q) is a member of the "A Disintegrin And Metalloprotease", or ADAM, family. TACE expression is largely constitutive, but the surface pool of the enzyme appears to be down regulated following cell activation. Cleavage by TACE generates the soluble form of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) that has been associated with inflammation. Cell activators increase the rate of cleavage, increasing the amount of TNF- $\alpha$  shedding. Inhibitors of TACE are currently being sought to treat inflammatory disease.

In another example, the neuropathology of Alzheimer's disease is characterized by the accumulation of extracellular protein deposits in the brain. These deposits include the amyloid containing plaques and amyloid in vessel walls. The major component of an amyloid plaque is a 39-42 amino acid residue self-aggregating peptide called  $\beta$ -amyloid ( $A\beta$ ). Considerable progress has been made in understanding the mechanisms that cause the disease, especially following the identification of Amyloid Precursor Protein (APP) and presenilin (PS) gene mutations in familial forms of Alzheimer's disease. These mutations lead to increased levels of the  $A\beta$  peptide in the brain (Selkoe, *Physiological Rev* 81:741-766, 2001).

The  $A\beta$  peptide is a proteolytic fragment of APP, a transmembrane protein expressed throughout most tissues in the body. Figure 2 shows the structure of APP, the resulting proteolytic fragments, and the respective processing enzymes known to generate these fragments. The APP protein is processed by at least three different proteases including  $\alpha$ -secretase,  $\beta$ -secretase, and  $\gamma$ -secretase. The  $\beta$ -secretase, responsible for the amino-terminal cleavage, was recently identified and cloned (Sinha, *et al.*, *Nature* 402: 537-540, 1999). This protease preferentially releases  $A\beta$  starting at Asp-1 and Glu-11. The  $\gamma$ -secretase cleavage, releasing the carboxyl-termini of APP, apparently occurs in the predicted transmembrane domain of APP. The  $\gamma$ -secretase consists of a complex of proteins, the most important being presenilin 1 (Steiner, *Rev. Mol. Cell. Biol.* 1:217-224, 2000).

A less abundant and more hydrophobic  $A\beta$  species,  $A\beta$ 1-42, has recently been linked to early pathological changes seen in Alzheimer's disease. Mutations associated with familial forms of Alzheimer's disease have been shown to increase the cellular production of  $A\beta$ . The  $A\beta$  peptide is thus the key molecule in the pathogenic process leading to Alzheimer's disease, where  $A\beta$  forms protofibrils, fibrils, and

subsequently amyloid plaques. Increased production or decreased clearance of A $\beta$  initiates a process resulting in amyloid plaque formation and subsequently neuronal degeneration. Recent studies have suggested the aggregates of A $\beta$  (protofibrils) may be toxic entities contributing to neuronal death (Gotz *et al.*, *Science* 293:1491-1495, 2001).  
5 Hence, any treatment that lowers A $\beta$  peptide in the brain of Alzheimer patients would be of significant clinical value. Figure 1 summarizes current knowledge of the disease in a process called the amyloid cascade.

Numerous research programs are developing drugs that are aimed at reducing the presence of processed products of membrane proteins associated with  
10 disease, such as A $\beta$ . These programs are primarily focused on molecules and agents that function by increasing or decreasing the activities of the processing enzymes. For example, many efforts are focused on identifying inhibitors of  $\beta$ -secretase or  $\gamma$ -secretase. However, in neurons, only 5% of APP molecules go through the A $\beta$  generating pathway, while 95% of APP molecules are processed by  $\alpha$ -secretase, through the non-  
15 amyloidogenic pathway, inhibiting A $\beta$  formation (Lammish, *et al.*, *Proc. Natl. Acad. Sci. USA* 96:3922-3927, 1999). Another objective is to normalize the production of A $\beta$  by increasing the level of cleavage at the  $\alpha$ -secretase site. These approaches may reduce the formation of the processed product of interest, such as A $\beta$ , but may also increase the risk of producing other health related problems due to the involvement of the processing  
20 enzymes in the formation of other important biological molecules. For example, increasing the activity of  $\alpha$ -secretase reduces the abundance of A $\beta$ . However,  $\alpha$ -secretase is also involved in the formation of angiotensin converting enzyme (ACE), a regulator of blood pressure (Parvathy *et al.*, *Biochemistry* 37:1680-1685, 1998).

One approach, with less risk of affecting other important metabolic  
25 pathways, is to modulate the abundance of a processing product of interest by changing the enzymatic processing of the substrate membrane protein through a slight alteration in the structure of the substrate membrane protein. For example, studies of APP mutations located close to the  $\alpha$ -secretase cleavage site suggest that local  $\alpha$ -helicity contributes to cleavage efficacy presumably by direct interaction of the endoprotease with this structure  
30 (Sisodia, *Proc. Natl. Acad. Sci. USA* 89:6075-6079, 1992). Similarly, changes in the amino acid sequence of APP identified as the Swedish mutation (Mullan *et al.*, *Nature Genetics* 1:345-347 (1992)), change the structure of APP and increases processing of APP at the  $\beta$  cleavage site.

More specifically, the identification of a molecule (effector) that modifies the structure of a protein and consequently the activity of the protein or its ability to act as a substrate depends on the intrinsic structural nature of the protein and how it interacts with other structures in a biological system. Protein function relies on the amino acid composition of the protein and the three dimensional structure dictated by the amino acid sequence. A protein is acted upon by other proteins and structures in a biological system based on its structure and the structure of other interactive molecule(s). The structure of a protein can be changed by an interaction with another molecule (allosteric interaction), which can increase or decrease the activity of the protein or the susceptibility of being acted upon by another protein.

As a particular example, peptides are structures that can interact with a protein to change its structure and consequently the activity of the protein or its susceptibility to being acted upon by another protein. Peptides as structural effectors are attractive because very large structural diverse libraries can easily be generated by recombinant methods and readily screened with procedures that identify preferred phenotypic behavior. These peptide effectors can be used to validate the effectiveness of a structure to cause a desired structural change. The peptide structure can be used as a model compound structure to design and develop, for example, a peptidomimetic structure that would be biologically stable, readily pass over the blood brain barrier, and be suitable for an oral formulation.

Screening methods have been developed to identify peptides that affect cellular processes through specific binding to proteins (herein also referred to as "peptide effectors"). The utility of random peptide libraries is demonstrated by the numerous methods that have been developed to generate and screen large libraries of structurally diverse peptides. In addition to chemical strategies, such methods include systems that rely upon biological generation (*see, e.g.*, Scott and Smith, *Science* 249:386-390, 1990 (phage display); Kawasaki, US Patent 5,658,754 (*in vitro* ribosome display); Cull *et al.*, *Proc. Natl. Acad. Sci. USA* 89:1865-1869, 1992 (random peptide sequences expressed on the C-terminus of the lac repressor); Murray *et al.*, *Biotechnology* 13:366-372, 1995 (thioredoxin random peptide libraries expressed on the flagellin of *E. coli*); Brown, *Nat. Biotechnol.* 15:269-272, 1997 (repeating polypeptides expressed on the surface of bacteria); Gilchrist and Hamm, *Methods Enzymol.* 315:388-404, 2000 (peptides-on-plasmids); Wilson *et al.*, *Proc. Natl. Acad. Sci. USA* 98:3750-3755, 2001 (mRNA display); Kjaergaard *et al.*, *Appl. Environ. Microbiol.* 67:5467-5473, 2001 (fimbria-displayed

peptide libraries). Most recently, Rigel, Inc. has demonstrated the utility of *in vivo* introduction of random peptide libraries to identify peptides that alter phenotypic changes in a mammalian cell (*See, e.g., Kinsella et al., J. Biol. Chem.* 277:37512-37518, 2002).

However, current methods do not allow the identification of peptide  
5 effectors that interact with membrane proteins in the cellular secretory pathways and, therefore, are not suited for identification of peptides that will affect the processing of the membrane protein during transience through the secretory pathways. While some methods have been developed to screen small peptides and polypeptides intracellularly in the cytoplasm (*see, e.g., Fields and Song, Nature* 340:245-46, 1989; Cull *et al., Proc. Natl.*  
10 *Acad. Sci. USA* 89:1865-69, 1992; Lu *et al., Biotechnology (NY)*13:366-72, 1995; International Patent Publication WO 99/24617; Norman *et al., Science* 285:591-95, 1999); International Patent Publication WO 98/39483), membrane proteins and their processing enzymes, *i.e.,* APP and APP processing enzymes, can be sequestered in compartments that do not mix with most other cytosolic molecules or organelles. For this reason, the current  
15 methods may not preserve the native secretory environment of a membrane protein.

In addition, current methods suffer from various disadvantages that limit the efficient identification of therapeutically promising peptides that act within the extracellular space. Consequently, current methods are also not suited for efficient identification of peptides that affect the processing or membrane proteins on the cell  
20 surface. Most of the screening methods that employ conventional peptide libraries (*e.g.,* phage display libraries, combinatorial libraries, peptide mimetic libraries, and one-bead-one structure combinatorial libraries) demonstrate only binding to targets *in vitro*. The normal structure, activity, and any necessary regulatory molecule(s) may be lost when extracellular proteins are purified or removed from their native, extracellular environment.  
25 Thus, these methods often fail to identify peptides that bind to extracellular targets with corresponding physiological effects *in vivo*.

Further, current *in vitro* screening methods also suffer from the disadvantage that the normal structure, activity, and any necessary regulatory molecule(s) may be lost when proteins or other macromolecules are purified or removed from their  
30 native environment. Peptides that would normally be effector molecules of native macromolecules may not bind to structurally altered targets. Non-native targets are also more likely than native targets to non-specifically bind physiologically irrelevant peptides. Further, even if purified target molecules retain native structure and activity, existing screening methods can produce poor or misleading results because the assay conditions

are not representative of the local extracellular environment *in vivo*. Local environments can significantly influence the accessibility of target molecules to peptides or the specificity or avidity of peptide binding.

Conventional screening methods also typically utilize target molecules that are attached to non-physiological surfaces, such as plastic, glass, or polymeric matrices. This association with a non-physiological surface introduces impediments to identifying peptides that interact specifically with protein or other macromolecular target molecules. Many macromolecular target molecules that are attached to a non-physiological surface denature onto that surface. Native binding sites on the surface of targets can be lost and other sites not normally displayed on the surface of targets can be unmasked, exposing such physiologically irrelevant sites to the peptides. This problem can result in the identification of peptides that only bind non-specifically to targets. The mode of attachment can also bias how target molecules are exposed on the surface and can result in a spatial orientation where only one set, or a limited set, of potential binding sites are exposed to the peptides. When this occurs, functionally important peptide binding sites on targets can be inaccessible during screening. Another impediment is that the binding kinetics and binding constants of freely soluble, interacting molecules can be altered when one is attached directly to a non-physiological surface. This problem is a well-known phenomenon that can either increase or decrease the specificity and avidity of peptide binding to targets and can lead to the identification of peptides that are ineffective in subsequent, functional screens (*see, e.g.,* Vijayendran and Leckband, *Anal. Chem.* 73:471-480, 2001; Butler, *Methods* 22:4-23, 2000).

Further, chemical-based combinatorial peptide libraries, consisting of small peptides that are not attached to a soluble carrier molecule or a hydrophilic matrix, suffer from the disadvantage that many short peptides are not soluble under physiological conditions, such as in the presence of undiluted blood, plasma, serum, or other complex biological fluids. Organic solvents such as methanol, ethanol, or DMSO have been required in prior screens to maintain the solubility of many peptides in the library. These organic solvents can denature many potential target or non-target proteins and other macromolecules during screening and result in the identification of poor-quality peptide candidates.

An additional disadvantage experienced with methods using phage- and bacteria-display peptide libraries is the prevalence of high backgrounds due to nonspecific binding of phage or bacteria to the targets. Such background can occur when screening is

conducted in physiologic environments, thereby causing many irrelevant peptide candidates to be selected. Typically, the nonspecific binding of phage and bacteria can be reduced by screening in the presence of high concentrations of salt, denaturants (*e.g.*, urea or guanidine-HCl), protein, or detergent, or other non-physiological conditions (*e.g.*,  
5 elevated temperatures, such as above 37°C). In contrast, physiological screening conditions for the identification of peptides usually replicate the conditions in which the target molecules normally express their activities (*e.g.*, human blood at 37°C). However, the complexity of macromolecules (*e.g.*, blood) present under physiological conditions can lead to a high level of nonspecific binding of peptide-displaying phage or bacteria, such  
10 that the library's diversity can be significantly reduced.

There is a need for screening methods that identify molecular effectors that specifically bind to a membrane protein substrate to alter its processing and to modulate the amount of processing product(s), rather than identifying agents that generally affect the activities of the processing enzymes themselves. The methods should provide for the  
15 identification of molecular effectors that modulate the processing of a membrane protein under conditions that preserve the molecular and cellular constituents of the secretory pathways as well as replicate the complex physiological conditions of the extracellular environment. Because maintaining the complex conditions native to those present during membrane protein processing will reduce non-specific binding events, retain native  
20 molecular conformations and kinetics, and maintain the presence of regulatory molecules, the disclosed physiological and secretory-based screens are more likely to identify agents that alter membrane protein processing, including agents that alter the production of a processing product of interest. The present invention provides such methods which are further set forth herein.

25

#### SUMMARY OF INVENTION

The present invention generally relates to methods for identifying an agent that alters processing of a membrane protein of interest. In one aspect, the method includes contacting the agent with an animal host cell that expresses the membrane  
30 protein, or a functional fragment thereof, and at least one processing enzyme of the membrane protein and detecting an altered processing product on the surface of the host cell to identify the agent that alters the processing of the membrane protein. Membrane protein processing enzyme(s) expressed by the host cell can include, for example, a secretase or a sheddase, *i.e.*, a protease or a phospholipase. The alteration of membrane

protein processing detected can be, for example, processing resulting in a decreased production of a soluble form of the membrane protein. In addition, the soluble protein demonstrating decreased production as a result of the altered membrane protein processing can be a soluble protein associated with an increased risk of disease, such as, for example, 5 inflammation, diabetes, cancer, Alzheimer's disease, Parkinson's disease, and the like.

The animal host cell expressing the membrane protein and membrane protein processing enzyme(s) can be, for example, a mammalian host cell. The animal host cell can be a recombinant host cell or, alternatively, an isolated host cell expressing endogenous membrane protein and membrane protein processing enzyme(s).

10 In certain embodiments, detecting the altered membrane protein processing includes assessing the relative presence or absence of at least one species of a processed membrane protein fragment on the surface of the host cell. As a specific example, species of amyloid precursor protein (APP) fragments assessed can include, such as, APPs- $\alpha$ , APPs- $\beta$ , or APPs- $\gamma$ , can be measured. The assessment of the relative presence or absence 15 of at least one species of a membrane protein fragment can include, for example, contacting the host cell with at least one detectably labeled marker that specifically binds to the species of membrane protein fragment and detecting the bound, labeled marker. Markers for detection of the absence or presence of membrane protein fragments can be, for example, an antibody that binds to a predetermined epitope of the membrane protein or 20 membrane protein fragment. In certain embodiments, the assessment of the relative presence or absence of the membrane protein fragment can include determining a ratio of the detection signals of at least two labeled antibodies specific for at least two different epitopes of the membrane protein or a membrane protein fragment. Detection of altered membrane protein processing on the surface of the host cell can include, for example, the 25 use of a flow cytometer or sorter.

The agent contacted with the host cell can be, for example, a small molecule or a biomolecule. In certain embodiments, the biomolecule contacted with the host cell is a peptide. The agent can come from a compound library such as, for example, a combinatorial chemical library, a natural products library, or a peptide library. The 30 agent can be an allosteric effector of the membrane protein.

In certain embodiments, the agent is contacted with the host cell under substantially physiological conditions. Substantially physiological conditions can include the presence of a complex biological fluid, such as, for example, blood, serum, plasma, or

cerebral spinal fluid (CSF).

In embodiments where the host cell is contacted with a peptide, the peptide can be produced, for example, by transcription and translation from an oligonucleotide encoding the peptide. The length of the oligonucleotides encoding the peptide can be, for example, about 18 to about 120 nucleotides, about 21 to about 60 nucleotides, or about 36 to about 60 nucleotides. In one embodiment, the contacting of the peptide with the host cell includes introducing an expression vector, the expression vector including the oligonucleotide encoding the peptide, into the host cell. The host cell into which the expression vector is introduced expresses and displays the peptide within the secretory pathway and on the cell surface.

The oligonucleotides introduced into the host cell can be, for example, from an expression library that includes oligonucleotide inserts, a majority of these oligonucleotides having different sequences encoding different peptides. In certain embodiments, the sequence of the oligonucleotides is randomized. The expression library is introduced into animal host cells that express the membrane protein and at least one membrane protein processing enzyme. Host cells into which the expression library is introduced express and display the different peptides within the secretory pathway and on the extracellular cell surface. In certain embodiments, the different peptides are displayed by the host cells under substantially physiological conditions.

In other embodiments, a subset of host cells exhibiting altered membrane protein processing are selected from the host cells. From this subset of host cells, a sub-library of the expression library is identified, the sub-library including at least one oligonucleotide that encodes a peptide that alters the processing of the membrane protein.

In certain embodiments, the host cells into which the expression library is introduced can be enriched for host cells displaying the different peptides. The host cells can be enriched by including a selectable marker in the expression construct. The expression construct can be, for example, V5, FLAG, or thioredoxin. Selection for the marker can include, for example, magnetic bead selection fluorescence-activated cell sorting. In certain embodiment, host cells enriched for cell displaying peptides can express a high copy number of the different peptides.

In one embodiment, the peptide is displayed as a fusion protein with a presentation molecule. The presentation molecule can be, for example, CD24, IL-3 receptor, protein A, or thioredoxin. The fusion protein can further include a marker epitope, such as, for example, polyhistidine, V5, FLAG, or myc and the like. The fusion

protein can also include a signal for a glycoposphatidylinositol (GPI) anchorage.

In other embodiments, the expression library can be pre-enriched for oligonucleotide(s) encoding peptides that specifically bind to the membrane protein of interest prior to introduction of the library into the host cells. Pre-enrichment can include  
5 introducing the expression library into a phage display vector which can express the peptides encoded by the oligonucleotide sequences on the surface of the phage; expressing the different peptides on the surface of the phage; selecting a subset of phage particles that express peptides that specifically bind the membrane protein; and recovering the oligonucleotide sequences from the selected phage particles. The pre-enriched expression  
10 library can be introduced into animal host cells expressing the membrane protein and at least one membrane protein processing enzyme. Host cells into which a pre-enriched library has been introduced express and display the membrane protein-binding peptide(s) within the secretory pathway and on the extracellular cell surface. A subset of host cells that exhibit altered membrane protein processing is selected from host cells expressing the  
15 pre-enriched library. From this subset of host cells, a sub-library of the pre-enriched expression library is identified, the sub-library including at least one oligonucleotide that encodes a membrane protein-binding peptide that alters the processing of the membrane protein.

A further understanding of the nature and advantages of the invention will  
20 become apparent by reference to the remaining portions of the specification.

#### BRIEF DESCRIPTION OF THE DRAWING

Figure 1 depicts the amyloid cascade leading to Alzheimer's disease.

Figure 2 depicts a schematic diagram of the  $\beta$ -amyloid precursor protein  
25 (APP) and its principal metabolic derivatives. The top diagram depicts the largest of the known APP alternative spliced forms, comprising 770 amino acids. A single transmembrane domain (TM) at amino acids 700-723 is indicated by vertical dotted lines. The  $\beta$ -amyloid ( $A\beta$ ) fragment includes 28 amino acids outside the membrane plus the first 12-14 residues of the TM domain. Arrows indicate sites of the proteolytic cleavage by  
30 processing enzymes. The various proteolytic fragments are labeled. (Selkoe, *Physiological Rev.* 81:741-767, 2001).

Figure 3 depicts a representation of the expression cassette for the expression of random peptide and presentation protein for the retroviral construction for

the identification of effector peptides of a membrane protein.

Figure 4 depicts a representation of the presentation protein being expressed on the surface of a cell with random peptide sequence in the configuration of a cysteine loop.

5                   Figure 5 depicts APP on the surface of a cell with labeled fragments, cleavage sites, antibodies recognizing fragments of APP, and strategies of using ratios of fluorescence to detect altered processing of APP.

                    Figure 6 depicts a representation of one example of an expression vector, designated pIcoDual, encoding a CD24 V5 fusion protein and a thioredoxin-FLAG fusion  
10                   protein, which is suitable for use in the present invention.

                    Figure 7 depicts a representation of an expression vector designated pIcoFLAGXa, encoding a CD24 V5 fusion protein and a thioredoxin-FLAG fusion protein where the Factor <sup>1</sup>X<sub>a</sub> restriction cleavage amino acid sequence, Ile-Glu-Gly-Arg-X, SEQ. ID NO:5, has been inserted at the random peptide site.

15                   Figure 8 depicts a representation of Thy 1 - EM $\alpha$ /EM $\beta$ <sub>S</sub> (S) and Thy 1-EM $\alpha$ /EM $\beta$ <sub>M</sub> (M) expression constructs for *in vivo* expression of effector peptides in transgenic mice. "EM $\alpha$ /EM $\beta$  sequence" denotes a nucleotide coding sequence for either an EM $\alpha$  peptide (*i.e.*, an effector peptide that inhibits APP processing by B-secretase).

## 20                   DESCRIPTION OF THE SPECIFIC EMBODIMENTS

                    The present invention provides screening methods for the identification of molecules and agents, including peptides and other small molecules, that alter processing of a membrane protein of interest and that thereby alter the production of processed  
25                   portions of the membrane protein. The membrane protein of interest is one that is processed either during transit to the membrane surface or at the membrane surface. Products of processing of the membrane protein are those that have been associated with a disease state, such as inflammation, cancer, diabetes, Alzheimer's disease, Parkinson's disease, and the like. The screening methods provided allow for the identification of  
30                   effector agents that can increase or decrease cleavage of the membrane protein, or a functional fragment thereof, at processing enzyme cleavage sites that correlate with the production of a processed product of interest. These screening methods can facilitate the development of therapeutic molecules for the treatment of inflammatory conditions, cancer, diabetes, Alzheimer's disease (AD), Parkinson's disease, and the like by correcting

or partially correcting imbalances in the activities of membrane protein processing enzymes, such as a secretase, or "shedase", that are implicated in the cause of the disease of interest.

5                   Prior to setting forth the invention in more detail, it may be helpful to a further understanding thereof to set forth definitions of certain terms as used hereinafter.

### Definitions

10                   The terms "membrane protein processing enzyme" refers to proteolytic enzymes involved in post-translational modification of a membrane protein of interest, such as for example, amyloid precursor protein (APP) during transience through secretory pathways in a cell (including, *e.g.*, the trans Golgi network and secretory vesicles) or on the cell surface. Proteolytic processing of the membrane protein of interest affects the relative amount of the processed membrane protein produced by the cell. For example, APP processing enzymes include, for example,  $\alpha$ -secretase,  $\beta$ -secretase, and  $\gamma$ -secretase.

15                   The term "altered membrane protein processing" refers to a change in the relative amounts of one or more membrane protein fragments produced by a cell. APP fragments, for example include, APPs- $\alpha$ , APPs- $\beta$ , and APPs- $\gamma$  (see Figure 2). Because the relative amount of one or more APP fragments is correlative of the amount of A $\beta$  produced, "altered APP processing" as used herein also generally refers to changes in APP processing that result in a change in the amount of A $\beta$  produced by a cell.

20                   The terms "agent," "molecule," and "compound" as used herein are synonymous and refer generally to molecules potentially capable of structural interactions with cellular constituents through non-covalent interactions, such as, for example, through hydrogen bonds, ionic bonds, van der Waals attractions, or hydrophobic interactions. For example, agents will most typically include molecules with functional groups necessary for structural interaction with proteins, glycoproteins, and/or other macromolecules, particularly those groups involved in hydrogen bonding.

25                   Agents can include small organic molecules such as, for example, aliphatic carbon or cyclical carbon (*e.g.*, heterocyclic or carbocyclic structures and/or aromatic or polyaromatic structures, and the like). These structures can be substituted with one or more functional groups such as, for example, an amine, carbonyl, hydroxyl, or carboxyl group. In addition, these structures can include other substituents such as, for example,

hydrocarbons (*e.g.*, aliphatic, alicyclic, aromatic, and the like), nonhydrocarbon radicals (*e.g.*, halo, alkoxy, acetyl, carbonyl, mercapto, sulfoxy, nitro, amide, and the like), or hetero substituents (*e.g.*, those containing non-carbon atoms such as, for example, sulfur, oxygen, or nitrogen).

5 Agents can also include biomolecules. "Biomolecules" refer to classes of molecules that exist in and/or can be produced by living systems as well as structures derived from such molecules. Biomolecules typically include, for example, proteins, peptides, saccharides, fatty acids, steroids, purines, pyrimidines, and derivatives, structural analogs, or combinations thereof. Biomolecules can include one or more functional  
10 groups such as, for example, an amine, carbonyl, hydroxyl, or carboxyl group.

Agents include those synthetically or biologically produced and can include recombinantly produced structures such as, for example, peptide-presenting fusion proteins. The term "fusion protein" refers to a polymer of amino acids produced by recombinant combination of two or more sequence motifs and does not refer to a specific  
15 length of the product; thus, a fusion protein can include a peptide sequence joined to an affinity label such as, for example, 6-histidine.

The terms "effector agent" or "molecular effector" as used herein refer to molecules that affect protein interactions with other macromolecules. "Molecular effector of membrane protein processing" thus refers to a molecule that alters the processing of a  
20 membrane protein of interest through, for example, interactions with the membrane protein or processing enzymes or the membrane protein.

The term "specific binding" refers to the direct interaction between an agent and the membrane protein, or a functional fragment thereof. An interaction between the agent and the membrane protein, or the functional fragment, can be detected either by  
25 direct or indirect analysis.

The term "allosteric effector" refers to an effector agent that activates or inhibits a particular protein activity or interaction by specifically binding to the protein to change its conformation. "Allosteric effector of the membrane protein" thus refers to an agent that specifically binds to the membrane protein, or a functional fragment thereof,  
30 and changes its conformation such that processing by one or more processing enzyme of the membrane protein is altered. The specific binding site of an allosteric effector is referred to herein as an "allosteric site."

The term "host cell" refers to a cell that can serve as a vehicle to test effector agents that can be introduced by several means. Host cells suitable for the present

invention are those that express the membrane protein, or a functional fragment thereof, and one or more membrane protein processing enzymes. In one particular example, the processing enzymes associated with APP include, *e.g.*,  $\alpha$ -,  $\beta$ -, and/or  $\gamma$ -secretase. In addition, suitable host cells for use in the present invention typically are animal cells, particularly mammalian cells. Host cells can also be "recombinant host cells." The term "recombinant host cell" as used herein means a host cells that expresses one or more recombinant proteins, including, for example, recombinant membrane protein, or a functional fragment thereof, and/or one or more processing enzymes of the membrane protein. Examples of suitable host cells include human embryonic kidney (HEK) cells, human neuroblastoma cell lines, Ba/F3, AC2 (*see, e.g.*, Garland and Kinnaird, *Lymphokine Res.* 5:S145-S150 (1986)), B9, HepG2, MES-SA and MES-SA/Dx5 cells. The host cell can serve as a recipient for a genetic library that is introduced by any one of several procedures. The host cell serving as a recipient of a genetic library often allows replication and segregation of a vector containing a library insert. In certain embodiments, however, replication and segregation are irrelevant; expression of a library insert is all that is required.

The terms "genetic library" refers to a collection of nucleic acid fragments that can individually range in size from about a few base pairs to about a million base pairs. Typically, as used in the context of the present invention, a genetic library comprises random or semi-random oligonucleotides that encode peptides or polypeptides. The oligonucleotides can have an average length of, for example, from about 10 bases to about 60 bases. In certain embodiments, a library is contained as inserts in a vector capable of propagating in certain host cells, such as bacterial and/or mammalian cells.

The term "compound library" as used herein refers to any collection of agents that includes a plurality of molecular structures. Compound libraries can include, for example, combinatorial chemical libraries, natural products libraries, and peptide libraries, further described *infra*. In certain embodiments, peptide libraries can be generated by transcription and translation from nucleic acid sequences included within a genetic library.

The term "sub-library" refers to a portion of a compound library or genetic library that has been isolated by methods according to the present invention.

The term "insert" in the context of a genetic library refers to an individual nucleic acid fragment that is typically inserted into single vector (*e.g.*, an expression

vector) or an expression construct.

The term “coverage” in the context of a genetic library refers to the amount of redundancy of the genetic library. It will be appreciated by those skilled in the art that the redundancy of a genetic library is generally related to the probability that a specific  
5 sequence is actually present within the nucleic acid sequences of that library. Coverage is the ratio of the number of library inserts, such as peptide-encoding oligonucleotides, multiplied by the average insert size divided by the total complexity of the nucleic acid sequences that the library represents.

The term “vector” refers to a nucleic acid sequence that is capable of  
10 propagating in a particular host cell and that can accommodate inserts of heterologous nucleic acid. Typically, vectors are manipulated *in vitro* to insert heterologous nucleic acids into a cloning site. A vector can be introduced into a host cell in a stable or transient manner, such as by transformation, transfection, or infection by a viral vector.

The term “expression vector” refers to a vector designed to express an  
15 inserted nucleic acid. Such vectors can contain, for example, one or more of the following operably associated elements: a promoter located upstream of the insertion site (*e.g.*, a cloning site) of the nucleic acid, a transcription termination signal, a translation termination signal and/or a polyadenylation signal. An expression vector can also include a selectable marker, such as a drug resistance gene (*e.g.*, hygromycin or neomycin  
20 resistance). (*See, e.g., Santerre et al., Gene 30:147-156 (1984)*). The expression vector can also include sequences for packaging into viral particles.

The term “high copy number” refers to expression on an extracellular surface of a host cell of at least several hundred to several thousand molecules encoded by a library insert.

25 The term “expression” in the context of a nucleic acid refers to transcription and/or translation of the nucleic acid into mRNA and/or protein.

The term “expression library” refers to a plurality of copies of an expression construct or vector, a majority of the copies of the construct or vector containing inserts of nucleic acid fragments from the genetic library.

30 The term “presentation molecule” refers to a polypeptide that can be used to display a peptide or polypeptide as part of a fusion protein.

The term “stable expression” refers to the continued presence and expression of a nucleic acid sequence in a host cell for a period of time that is at least as long as that required to carry out the methods according to the present invention. Stable

expression can be achieved by integration of the nucleic acid into a host cell chromosome, or engineering the nucleic acid so that it possesses elements that ensure its continued replication and segregation within the host (*e.g.*, an expression vector or an artificial chromosome) or alternatively, the nucleic acid can contain a selectable marker (*e.g.*, a  
5 drug resistance gene) so that stable expression of the nucleic acid is ensured by growing the host cells under selection conditions (*e.g.*, drug-containing medium) or it can be introduced as a viral genome that becomes integrated in the host genome.

The term “specific binding” refers to the direct interaction between an agent and the membrane protein. An interaction between the agent and the membrane  
10 protein can be detected either by direct or indirect analysis.

The terms “physiological conditions” and “substantially physiological conditions” refer to conditions that are normally present, or that substantially approximate those normally present, in an extracellular space, on an extracellular surface (*e.g.*, on a cell membrane), in a Golgi network, secretory vesicle, and/or in a complex biological fluid.  
15 For example, “substantially physiological conditions” can be those present when extracellular targets are active or express their activities (*e.g.*, enzymatic activity, binding to a receptor, substrate, scaffolding molecule, or other binding partner, and the like).

The term “complex biological fluid” refers to a biological fluid, such as, for example, autologous (*i.e.*, from the same animal), homologous (*i.e.*, from an animal of the  
20 same species), or heterologous (*i.e.*, from a different species) blood, plasma, serum, cerebral spinal fluid (CSF), and the like. Complex biological fluids can be either undiluted or substantially undiluted. The term “substantially undiluted complex biological fluid” refers to a complex biological fluid that is either undiluted or diluted in physiological buffers to typically no less than about 50% concentration. Substantially  
25 undiluted complex biological fluids, *i.e.*, no less than approximately 50% of undiluted fluids, have substantially the same ionic composition and strength and substantially the same macromolecular structures in solution, in approximately the same absolute concentrations, as the undiluted fluid.

The terms “transformation” or “transfection” refer to the process of  
30 introducing nucleic acids into a recipient (*e.g.*, host) cell. This is typically detected by a change in the phenotype of the recipient cell. The term “transformation” is generally applied to microorganisms, while “transfection” is used to describe this process in cells derived from multicellular organisms.

The terms “infect” or “infected” refer to the process of introducing nucleic

acids into a recipient (*e.g.*, host) cell by means of a viral vector.

The term “flow sorter” refers to a device that analyzes light emission intensity from cells or other objects and separates these cells or objects according to parameters such as light emission intensity. Suitable flow sorters include, for example, a  
5 fluorescence-activated cell sorter (FACS), a spectrophotometer, microtiter plate reader, a charge coupled device camera and reader, a fluorescence microscope, or similar device.

The terms “bright” and “dim” in the context of a flow sorter refer to the intensity levels of fluorescence (or other modes of light emission) exhibited by particular cells: Bright cells have high intensity emission relative to the bulk population of cells and,  
10 by inference, high levels of reporter; dim cells have low intensity emission relative to the bulk population and, by inference, low levels of reporter.

The term “bead selection” refers to the use of beads to selectively remove cells from a mixture of cells. Beads can include a macromolecule, such as an antibody or other binding partner. In certain embodiments, the bead selection uses derivatized  
15 magnetic beads. For example, cells expressing a FLAG epitope on the cell surface can be pre-selected on magnetic beads that are coated with anti-FLAG antibody. The magnetic beads can then be collected using a strong magnetic field.

#### Selection/Establishment of Host Cell Lines

20 The host cells used in the screening methods according to the present invention express both the membrane protein of interest, for example, TGF- $\alpha$ , TNF- $\alpha$ , APP, TNFR, and the like, and one or more processing enzyme of the membrane protein, such as, in the example of APP,  $\alpha$ -secretase,  $\beta$ -secretase, or  $\gamma$ -secretase. These host cells  
25 can be isolated cells that endogenously express the membrane protein and/or at least one of the processing enzymes of the membrane protein. In addition, the host cells can be recombinant host cells expressing recombinant forms of the membrane protein, including functional fragments of the membrane protein that are properly processed, and/or at least a recombinant form of one processing enzyme. Host cells can, therefore, exhibit  
30 endogenous expression with respect to one membrane protein or enzyme molecule while being a "recombinant host cell" with respect to another such molecule.

In one exemplary embodiment of the invention, the host cells are recombinant with respect to the membrane protein, such as for example, TGF- $\alpha$ , TNF- $\alpha$ , APP, TNFR, and the appropriate secretase, TGF- $\alpha$  secretase, TNF- $\alpha$  secretase,  $\alpha$ -secretase

and  $\beta$ -secretase, and TNFR secretase, respectively. DNA encoding the membrane protein of interest can be obtained, for example, from the American Type Culture Collection (ATCC) or the Innovative Molecular Analysis Technologies Program of the National Cancer Institute, National Institutes of Health (IMAT) or are alternatively obtained by  
5 methods known in the art such as, *e.g.*, PCR amplification and DNA sequence analysis verification. The cDNA can be inserted into, *e.g.*, a mammalian expression vector and transfected into a parental mammalian cell line (*e.g.*, a neuroblastoma cell line or human embryonic kidney cell line (HEK)) using known methods such as, for example, electroporation. These cell lines can be assessed for expression of the membrane protein  
10 using methods known in the art such as, for example, fluorescent microscopy or FACS analysis using antibodies specific for the membrane protein of interest. For example, antibodies to various APP fragments, including APPs- $\beta$  (such as for example, A3 or 1G7 specific to APP midregion, Koo *et al.*, *J.Biol.Chem.* 269:17386-17389, 1994), APPs- $\alpha$  (6E10 specific to the carboxyl terminal end of APPs- $\alpha$  or the region of APP between the  $\beta$   
15 and  $\alpha$  cleavage sites, Pirttila *et al. Neurol. Sci.* 127:90-95, 1994, McLaurin *et al., Nat. Med.* 11:1263-1269, 2002), and p3 (4G8, Pirttila *et al. Neurol. Sci.* 127:90-95, 1994, McLaurin *et al., Nat. Med.* 11:1263-1269, 2002). These cells can then transfected with one or more expression vectors, each expression vector encoding one or more APP processing enzymes. For example, two separate expression vectors, one encoding  $\alpha$ -  
20 secretase and the other encoding either  $\beta$ -secretase or  $\gamma$ -secretase, can be transfected into the host cells. DNA encoding the secretases can be obtained, for example, from the ATCC or IMAT or are alternatively obtained by methods known in the art such as, *e.g.*, amplification and DNA sequence analysis verification.

### 25 Compound Libraries

In one embodiment of the invention, compound libraries are contacted with host cells to screen for effector agents that alter processing of the membrane protein of interest. Compound libraries can be prepared from, for example, a historical collection of  
30 compounds synthesized in the course of pharmaceutical research; libraries of compound derivatives prepared by rational design (*see generally*, Cho *et al., Pac. Symp. Biocompat.* 305-316, 1998; Sun *et al., J. Comput. Aided Mol. Des.* 12:597-604, 1998; each incorporated herein by reference in their entirety), such as, for example, by combinatorial chemistry (*see discussion of combinatorial chemical libraries, infra*); natural products

libraries (libraries including, for example, complex extracts derived from microorganisms such as bacteria, algae, fungi, yeasts, molds, various plants or plant parts, animal fluids, secretions and the like, and others; such libraries can, for example, include those formed in the course of pharmaceutical research); peptide libraries (*see* discussion of peptide  
5 libraries, *infra*); and the like.

*Combinatorial Chemical Libraries:* In other embodiments, compound libraries can be prepared by syntheses of combinatorial chemical libraries (*see generally* DeWitt *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6909-6913, 1993; International Patent Publication WO 94/08051; Baum, *Chem. & Eng. News*, 72:20-25, 1994; Burbaum *et al.*,  
10 *Proc. Natl. Acad. Sci. USA* 92:6027-6031, 1995; Baldwin *et al.*, *J. Am. Chem. Soc.* 117:5588-5589, 1995; Nestler *et al.*, *J. Org. Chem.* 59:4723-4724, 1994; Borehardt *et al.*, *J. Am. Chem. Soc.* 116:373-374, 1994; Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926, 1993; and Longman, *Windhover's In Vivo The Business & Medicine Report* 12:23-31, 1994; all of which are incorporated by reference herein in their entirety.)

The following articles describe methods for selecting starting molecules and/or criteria used in their selection: Martin *et al.*, *J. Med. Chem.* 38:1431-1436, 1995; Domine *et al.*, *J. Med. Chem.*, 37:973-980, 1994; Abraham *et al.*, *J. Pharm. Sci.* 83:1085-1100, 1994; each of which is hereby incorporated by reference in its entirety. Methods of making combinatorial libraries are known in the art, and include the following: U.S. Patent  
20 Nos. 5,958,792; 5,807,683; 6,004,617; 6,077,954 which are incorporated by reference herein.

A "combinatorial library" is a collection of compounds in which the compounds of the collection are composed of one or more types of subunits. The subunits can be selected from natural or unnatural moieties, including dienes, aromatic or  
25 polyaromatic compounds, alkanes, cycloalkanes, lactones, dilactones, amino acids, and the like. The compounds of the combinatorial library differ in one or more ways with respect to the number, order, type or types of modifications made to one or more of the subunits comprising the compounds. Alternatively, a combinatorial library may refer to a collection of "core molecules" which vary as to the number, type or position of R groups  
30 they contain and/or the identity of molecules composing the core molecule. The collection of compounds is typically generated in a systematic way. Any method of generating a collection of compounds differing from each other in one or more of the ways set forth above can be a combinatorial library.

A combinatorial library can be synthesized on a solid support from one or more solid phase-bound resin starting materials. The library can contain ten (10) or more, typically fifty (50) or more, organic molecules which are different from each other (*i.e.*, ten (10) different molecules and not ten (10) copies of the same molecule). Each of the  
5 different molecules (different basic structure and/or different substituents) will be present in an amount such that its presence can be determined by some means (*e.g.*, can be isolated, analyzed, detected with a binding partner or suitable probe). The actual amounts of each different molecule needed so that its presence can be determined can vary due to the procedures used and can change as the technologies for isolation, detection and  
10 analysis advance. When the molecules are present in substantially equal molar amounts, an amount, for example, of 100 picomoles or more can be detected. Typical libraries include substantially equal molar amounts of each desired reaction product and typically do not include relatively large or small amounts of any given molecule(s) so that the presence of such molecules dominates or is completely suppressed in any assay.

15 Combinatorial libraries are generally prepared by derivatizing a starting compound onto a solid-phase support (such as a bead). In general, the solid support has a commercially available resin attached, such as a Rink or Merrifield Resin. After attachment of the starting compound, substituents are attached to the starting compound. For example, an aromatic (*e.g.*, benzene) compound can be bound to a support via a Rink  
20 resin. The aromatic ring is reacted simultaneously with a substituent (*e.g.*, an amide). Substituents are added to the starting compound, and can be varied by providing a mixture of reactants to add the substituents. Examples of suitable substituents include, but are not limited to, the following:

(1) hydrocarbon substituents, that is, aliphatic (*e.g.*, alkyl or alkenyl),  
25 alicyclic (*e.g.*, cycloalkyl or cycloalkenyl) substituents, aromatic, aliphatic and alicyclic-substituted aromatic nuclei, and the like, as well as cyclic substituents;

(2) substituted hydrocarbon substituents, that is, those substituents containing non-hydrocarbon radicals which do not alter the predominantly hydrocarbon substituent; those skilled in the art will be aware of such radicals (*e.g.*, halo (especially  
30 chloro and fluoro), alkoxy, mercapto, alkylmercapto, nitro, nitroso, sulfoxy, and the like);

(3) hetero substituents, that is, substituents that will, while having predominantly hydrocarbyl character, contain other than carbon atoms. Suitable heteroatoms will be apparent to those of ordinary skill in the art and include, for example,

sulfur, oxygen, nitrogen, and such substituents as pyridyl, furanyl, thiophenyl, imidazolyl, and the like.

*Natural Products Library:* In another embodiment of the invention, the compound library is a natural products library. The natural products library can be, for example, a library of natural products from diverse natural products sources (*e.g.*, such as those natural products accumulated during the course of pharmaceutical research) or, alternatively, a collection of compounds derived from a single natural products source (for example, one or more lysates, homogenates, or chemical extracts from, *e.g.*, microorganisms, plants, animal fluids, or other biological material such as that found in, *e.g.*, soil or peat).

In one embodiment, the source for generating the natural products library is a peat material. These materials commonly contain very large numbers of diverse compounds. In one specific embodiment, the natural products library is derived from a peat material obtained from Bonaparte Meadows, a peat bog near Bonaparte Lake, Washington, U.S.A. (*See* U.S. Patent No. 6,267,962.) Procedures related to the use and screening of peat material for certain uses are generally known in the art. (*See, e.g.*, U.S. Patent Nos. 6,267,962 and 6,365,634, incorporated herein by reference in their entirety.) For example, one general scheme of peat material extraction and fractionation involves an initial exposure to ethanol to extract molecules with a broad range of characteristics from non-polar to polar properties. Subsequent fractions can include, for example, those that are acidified or alkalized and subjected to phase separations with, *e.g.*, chloroform. Resulting fractions can be further fractionated by, *e.g.*, silica gel chromatography and/or reverse phase HPLC. Once a desired fraction is obtained, it can be buffer exchanged using, *e.g.*, standard procedures to facilitate its use according the particular screening method used.

*Peptide Libraries:* In one embodiment, compound pools can be prepared from peptide libraries. Generally, peptides ranging in size from about 4 amino acids to about 100 amino acids can be used, with peptides ranging from about 6 to about 40 being typical and with from between about 7 and 12 amino acids to about 20 being more typical.

In some embodiments, the library can comprise synthetic peptides. For example, a population of synthetic peptides representing all possible amino acid sequences of length N (where N is a positive integer), or a subset of all possible sequences, can

comprise the peptide library. Such peptides can be synthesized by standard chemical methods known in the art (*see, e.g., Hunkapiller et al., Nature* 310:105-111, 1984; Stewart and Young, *Solid Phase Peptide Synthesis*, 2<sup>nd</sup> Ed., Pierce Chemical Co., Rockford, IL, (1984)), such as, for example, an automated peptide synthesizer. Furthermore, if desired, 5 nonclassical amino acids or chemical amino acid analogs can be used in substitution of or in addition into the classical amino acids. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, 2-amino butyric acid,  $\gamma$ -amino butyric acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, 10 hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, selenocysteine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, C  $\alpha$ -methyl amino acids, N  $\alpha$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

15 In other embodiments, the peptide libraries can be produced by transcription and translation from a library of nucleic acid sequences. In one exemplary embodiment, an expression library comprising oligonucleotides encoding the library peptides is introduced into a host cell (*see Genetic Libraries, Expression Cassettes and Vectors, and Nucleic Acid Transfer, infra*).

### 20 Genetic Libraries

In one aspect of the invention, the screening methods include introducing an expression library into a host cell that expresses the membrane protein of interest, or a function fragment thereof, such as TGF- $\alpha$ , TNF- $\alpha$ , APP, TNFR, and the like, and one or 25 more processing enzyme(s) of the membrane protein.

The genetic libraries according to the present invention include a collection of at least partially heterogeneous nucleic acid fragments. Such nucleic acid fragments can include, for example, synthetic DNA or RNA, genomic DNA, cDNA, mRNA, cRNA, heterogeneous RNA, and the like. The nucleic acid fragments can represent, for example, 30 all or some portion of a population of nucleic acids, such as a genome, of a population of mRNAs, or some other set of nucleic acids that contain nucleic acid sequences of interest. The genetic libraries contain sequences in a form that can be manipulated.

The present invention typically uses genetic libraries that are derived from

synthetic DNA or from fragments of genomic DNA and/or cDNA from a particular organism. Such library sequences will typically range from about 10 bases to about 10 kilobases. The library sequences can optionally be oligonucleotides having, for example, an average length of from about 10 bases to about 60 bases.

5                   Methods of making synthetic DNA are known to those of skill in the art. (See, e.g., Glick and Pasternak, *Molecular Biotechnology: Principals and Applications of Recombinant DNA*, ASM Press, Washington, D.C. (1998).) Methods of making randomly sheared genomic DNA and/or cDNA, and of manipulating such DNA's, are also known in the art. (See, e.g., Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 3rd ed.,  
10 Cold Spring Harbor Publish., Cold Spring Harbor, NY (2001); Ausubel *et al.*, *Current Protocols in Molecular Biology*, 4th ed., John Wiley and Sons, New York (1999); which are incorporated by reference herein.) The details of library construction, manipulation and maintenance are also known in the art. (See, e.g., Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra*.)

15                   In some aspects, the library is made of synthetic nucleic acid fragments. For example, a population of synthetic oligonucleotides representing all possible sequences of length N (where N is a positive integer), or a subset of all possible sequences, can be the nucleic acids for the library. A population of synthetic oligonucleotides encoding all possible amino acid sequences of length N, or a subset of all  
20 possible sequences, can also be the nucleic acids for the library. Alternatively, a semi-random library can be used. For example, a semi-random library can be designed according to the codon usage preference of the host cell or to minimize the inclusion of translational stop codons in the encoded amino acid sequence. As an example of the latter, in the first position of each codon, equimolar amounts of C, A, and G and a one half-molar  
25 amount of T would be used. In the second position, A is used at a one half-molar amount while C, T, and G would be used in equimolar amounts. In the third position, only equimolar amounts of G and C would be used.

                    Synthetic oligonucleotides can optionally include any suitable *cis* regulatory sequence, such as, for example, a promoter, a translational start codon, a  
30 translational termination signal, a transcriptional termination signal, a polyadenylation signal, a cloning site (e.g., a restriction enzyme sites or cohesive end(s)), a sequence encoding an epitope, and/or a priming segment. For example, a library can include DNA fragments having a restriction enzyme site near one end, operably associated with an ATG start codon, a random or semi-random sequence of N nucleotides, a translational stop

codon, a primer binding site and a restriction enzyme site at the other end. Such a collection of fragments can be directly ligated into an expression construct, into a vector, into an expression vector, and the like. The fragments can be introduced as single stranded or double stranded DNA, and as either sense or antisense strands. As will be appreciated by the skilled artisan, double stranded nucleic acids can be formed, for example, by annealing complementary single stranded nucleic acids together or by annealing a complementary primer to the nucleic acid and then adding polymerase and nucleotides (*e.g.*, deoxyribonucleotide or ribonucleotide triphosphates) to form double stranded nucleic acids. Double stranded nucleic acids can also be formed by ligating single stranded nucleic acids (*e.g.*, DNA) into a site with 5' and 3' overhanging ends and then filling in the partially single stranded nucleic acids with a polymerase and nucleotide triphosphates. The details of manipulating and cloning oligonucleotides are known in the art. (*See, e.g.*, Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra.*)

The libraries most typically comprise nucleic acids that have coverage that exceeds the possible permutations of the nucleic acid of the library sequences. For example, a library can comprise a number of nucleic acids that exceeds the possible permutations of nucleic acid sequences by about 5 times, although greater and lesser amounts of redundancy are within the scope of the invention. The details of library construction, manipulation and maintenance are known in the art. (*See, e.g.*, Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra.*)

In an exemplary embodiment, a library is created according to the following procedure using methods that are well known in the art. Double stranded DNA fragments are prepared from random or semi-random synthetic oligonucleotides, randomly cleaved genomic DNA and/or randomly cleaved cDNA. These fragments are treated with enzymes, as necessary, to repair their ends and/or to form ends that are compatible with a cloning site in an expression vector. The DNA fragments are then ligated into the cloning site of copies of the expression vector to form an expression library. The expression library is introduced into a suitable host strain, such as an *E. coli* strain, and clones are selected. The number of individual clones is typically sufficient to achieve reasonable coverage of the possible permutations of the starting material. The clones are combined and grown in mass culture, or in pools, for isolation of the resident vectors and their inserts. This process allows large quantities of the expression library to be obtained in preparation for subsequent procedures described herein.

### Expression Cassettes and Vectors

In another aspect, expression cassettes and/or vectors are used to express peptides and/or fusion proteins encoded by sequences of an expression library. There are numerous expression cassettes and vectors known in the art which are readily available for use. (See, e.g., Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra*.) Some of these cassettes and vectors are tailored for use in specific cell types, while others can be used in a wide variety of cell types. In mammalian cells, viral transcriptional regulatory elements are a typical choice for driving expression of exogenous coding sequences, such as library sequences. An expression cassette or vector can also include one or more selectable markers to identify host cells that contain the expression vector and/or the expression library.

To effect expression of peptides, an expression cassette can include, for example, in a 5' to 3' direction relative to the direction of transcription, a promoter region operably associated with a cloning site for insertion of library sequence and a transcriptional termination region, optionally having a polyadenylation (poly A) sequence. The expression cassette can optionally include a ribosome binding sequence, a translation initiation codon, and/or a translational termination codon. A secretion signal and/or a domain for anchoring the expressed peptide to the cell surface are typically included adjacent the cloning site.

Suitable secretion signals include, for example, those from CD24. Suitable cell surface-anchoring domains include, for example, a signal for glycosylphosphatidylinositol (GPI) anchorage or a transmembrane domain (e.g., the transmembrane domain of CD24, IL-3 receptor, and the like).

To effect expression of the library sequences in host cells of a particular type, a promoter capable of conferring robust, high or moderately high expression of the library insert is preferred. Suitable promoter sequences can include, for example, enhancer and/or a TATA box sequences capable of binding an RNA polymerase (such as RNA polymerase II). The promoter can be constitutively active (such as a viral promoters), or it can be inducible. An inducible promoter can be used when controlled expression of library sequences is desired and/or to avoid toxic side effects associated with expression or over-expression of peptide sequences and/or fusion proteins. Suitable inducible promoters include, but are not limited to, interferon inducible promoter systems, the promoters for 3'-5' poly (A) synthetase or Mx protein (see, e.g., Schumacher *et al.*, *Virology* 203:144-148, 1994), the HLV-LTR, the metallothionein promoter (see, e.g.,

Haslinger *et al.*, *Proc. Natl. Acad. Sci. USA* 82:8572-8576, 1985), the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310, 1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, *Cell* 22:787-797, 1980), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl.*  
5 *Acad. Sci. USA* 78:1441-1445, 1981), and the like.

Other suitable promoters can be derived from housekeeping genes that are expressed at high or reasonably high levels. For example, the promoter for  $\beta$ -actin is useful for high expression. (*See, e.g.*, Qin *et al.*, *J. Exp. Med.* 178:355-360, 1993.) Similarly, the cytomegalovirus promoter and the translational elongation factor EF-1 $\alpha$   
10 promoter are other strong promoters useful for expression. In general, suitable promoters, such as housekeeping or viral gene promoters, can be identified using well known molecular genetic methods.

In certain embodiments, the cloning site is adjacent to one or more translational termination sequences, such that the length of any resulting expressed peptide  
15 is substantially the same as the coding region of the library sequence. As used herein, the phrase "substantially the same length" means that the length of the expressed peptide corresponds to the length of the coding region in the library sequence and can further encode, for example, a methionine residue corresponding to the start codon, any additional amino acids resulting from linker nucleic acids within the coding region, translational or  
20 post-translational modifications, one or more epitopes, and the like.

In some embodiments, the cloning site is flanked by epitopes. Suitable epitopes can include, for example, Xpress™ leader peptide (Asp-Leu-Tyr-Asp-Asp-Asp-Asp-Lys, SEQ ID NO:1; InVitrogen), a *myc* epitope (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn, SEQ ID NO:2; InVitrogen), the V5 epitope (Gly-Lys-Pro-Ile-Pro-Asn-Pro-  
25 Leu-Leu-Gly-Leu-Asp-Ser-Thr; SEQ ID NO:3), the FLAG tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys, SEQ ID NO:4, (*see, e.g.*, Hopp *et al.*, *Biotechnology* 6:1205-1210, 1988), the *lexA* protein, thioredoxin, FLAG, polyhistidine, and the like.

In an exemplary embodiment, to lend additional structure to the expressed peptide sequences, the cloning site can be flanked by sequences encoding cysteines such  
30 that the expressed peptide will include cysteine residues at the termini.

In certain embodiments, a cloning site is associated with the coding region of a fusion protein for extracellular display of the peptides (also referred to as a "presentation molecule"). Such a fusion protein can include, for example, (1) homologous

protein domains, protein fragments, or proteins as found in the host cell or on the host cell surface, and/or (2) heterologous protein domains, protein fragments, or proteins from another type of cell. The choice of fusion protein depends on the type of host cell(s), the stability of the fusion protein, the desired conformation of the expressed peptide (*e.g.*,  
5 constrained or unconstrained). Such a presentation molecule typically includes a signal sequence and a transmembrane domain.

The presentation molecule can display the peptide at or near the N-terminus, at or near the C-terminus, or internally to the presentation molecule. In an exemplary embodiment, the presentation molecule displays the peptide at the N-terminus  
10 and the C-terminal portion of the presentation molecule is anchored to the cell membrane by a transmembrane domain or GPI anchor. The presentation molecule can be modified to position the peptides at varying distances from the host cell surface to increase the probability of achieving the appropriate steric orientation for specific binding between peptides and the membrane protein of interest. In addition, spacers (*e.g.*, glycine spacers)  
15 can be included between the presentation molecule and the peptide to impart flexibility and minimize steric hindrance from the presentation molecule with peptide interactions in the extracellular space or in the secretory pathway, including interactions of the peptide with the membrane protein or the processing enzymes of the membrane protein. Such spacers can also be included between the presentation molecule and the cell surface-  
20 anchoring domain to impart flexibility at the cell surface.

Suitable presentation molecules can include, for example, lymphocyte antigen CD20, modified IL-3 receptor, CD24 (*see, e.g.*, Poncet *et al.*, *Acta Neuropathol. (Berl)* 91:400-408, 1996), protein A, and the like. Referring to Figure 6, the pIcoDual vector includes exemplary expression cassettes. For example, one expression cassette  
25 encodes a CD24-V5 fusion protein and includes one or more unique restriction sites for insertion of library sequences. Another suitable fusion protein includes *E. coli* thioredoxin and the FLAG epitope. At the junction between the thioredoxin and FLAG coding sequences, a unique *Xba*I restriction site permits insertion of library sequences into the fusion protein coding region.

30 An expression cassette can optionally be part of an expression vector. Suitable expression vectors are known in the art. (*See, e.g.*, Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra.*) In certain embodiments, a controlled plasmid amplification system is used for expression in mammalian cells. Such a system allows controlled plasmid amplification in a variety of cells. Increased plasmid copy number can also lead

to increased expression of the encoded peptides. High level expression of the peptides can increase the numbers of peptides displayed on an extracellular surface. Such a controlled amplification system also allows for sustained transient expression in mammalian cells. Sustained transient expression can be advantageous because typically 10 times as many  
5 cells exhibit transient expression as compared to stable transfection which can allow larger numbers of peptides to be effectively screened. Plasmid amplification also facilitates recovery of plasmids or sequences encoding peptides of interest.

In an exemplary embodiment, the controlled plasmid amplification system utilizes the SV40 replication system. The expression vector contains a fusion of the early  
10 promoter of SV40 and the coding region for Large T antigen, so that transcription of Large T antigen is under the control of the early promoter of SV40. The vector also contains the SV40 origin of replication. When this vector enters a cell, the SV40 early promoter promotes transcription of Large T antigen RNA. The RNA is translated into Large T antigen. Large T antigen binds to the SV40 origin and cause amplification of the plasmid.  
15 As Large T antigen concentrations rise in the cell, the binding of Large T antigen to the SV40 early promoter shuts down the SV40 early promoter and, consequently, Large T antigen RNA synthesis. The system, therefore, is self-regulating. As the plasmid copy number rises, there will not be an increase in production of Large T antigen that would continue to escalate plasmid amplification to the point of cell death. The amount of Large  
20 T antigen in a cell will be a function of the amount of Large T antigen RNA, the stability of the Large T antigen RNA, the stability of Large T antigen protein, the relative affinity for the origin of replication and the SV40 early promoter, and the reduction in the amounts of vector, Large T antigen RNA, and Large T antigen due to cell division. Because the amplification system is contained on a vector, plasmid amplification is typically not  
25 limited to the use of COS7 host cells, but rather plasmid amplification can be used for most mammalian cell types.

For other replication systems, the expression vector, if it is of viral origin, may not require propagation in a bacterial host. More typically, however, the vector is propagated in a bacterial host and contains sequences necessary for replication and  
30 selection in *E. coli*, such as, for example, a *colE1* replicon and an antibiotic resistance gene.

An expression vector can optionally contain one or more selectable markers. For example, suitable selectable markers for transfection of eukaryotic cells include the genes for hygromycin resistance, neomycin resistance, blasticidin resistance,

zeocin resistance, doxorubicin resistance, and the like. Suitable selectable markers for other cells include other antibiotic resistance genes and those complementing auxotrophies (e.g., amino acid auxotrophies). The expression vector can also optionally include a selectable marker to signal that the host cell contains the expression vector. Suitable  
5 selectable markers will include green fluorescent protein, or epitopes such as, for example, polyhistidine, the Xpress™ leader peptide (Asp-Leu-Tyr-Asp-Asp-Asp-Asp-Lys, SEQ ID NO:1; InVitrogen), a *myc* epitope (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn, SEQ ID NO:2; InVitrogen), the V5 epitope (Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr; SEQ ID NO:3), the FLAG tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys, SEQ  
10 ID NO:4, *see, e.g., Hopp et al., Biotechnology* 6:1205-1210, 1988), the *lexA* protein, or bacterial thioredoxin. Such markers can be detected, for example, by enzyme assay, by fluorescence using a flow sorter or similar device, using antibodies (e.g., a monoclonal or polyclonal antibody), using bead selection, and the like. When such markers are present on the cell surface, they can be used to isolate or to enrich for cells expressing the marker.

15

#### Nucleic Acid Transfer

A variety of methods can be used to transfer library sequences into host cells. (*See generally* Ausubel *et al., supra*; Sambrook *et al., supra*.) Some methods give rise primarily to transient expression in host cells (*i.e.*, the expression is gradually lost  
20 from the cell population). Other methods can generate cells that stably express the library sequences, though the percentage of stable expressers is typically lower than transient expressers. Such methods include viral and non-viral mechanisms for nucleic acid transfer.

Suitable mammalian cells include, for example, human embryonic kidney  
25 (HEK) cells, human neuroblastoma cell lines, K562, COS7, Ba/F3, AC2 (*see, e.g.,* Garland and Kinnaird, *Lymphokine Res.* 5:S145-S150, 1986), B9, HepG2, MES-SA, MES-SA/Dx5 cells, and the like. Animal host cells can include, but are not limited to, cells isolated from oncogenic tissues and tumors, including melanocyte, colon, prostate, leukocytes, liver, kidney, uterus, and the like. Certain cells and cell lines are available  
30 commercially from, for example, the American Type Culture Collection.

For viral vectors, the library sequences are typically carried into the host cell as part of the viral package. Depending on the type of virus, the nucleic acid can remain as an extrachromosomal element (*e.g.,* adenoviruses (*see, e.g., Amalfitano et al.,*

*Proc. Natl. Acad. Sci. USA* 93:3352-3356, 1996) or adeno-associated virus) or it can be incorporated into a host chromosome (e.g., retroviruses (Iida *et al.*, *J. Virol.* 70:6054-6059, 1996)).

For the transfer of non-viral expression vectors, many methods can be used. (See, e.g., Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra*.) One method for nucleic acid transfer is calcium phosphate coprecipitation of nucleic acid. This method relies on the ability of nucleic acid to coprecipitate with calcium and phosphate ions into a relatively insoluble calcium phosphate complex, which settles onto the surface of adherent cells on the culture dish bottom. Other methods employ lipophilic cations that bind nucleic acid by charge interactions while forming lipid micelles. These micelles fuse with cell membranes, introducing the nucleic acid into the host cell where it is expressed. Another method of nucleic acid transfer is electroporation, which involves the discharge of voltage from the plates of a capacitor through a buffer containing nucleic and host cells. This process disturbs the cell membrane sufficiently that nucleic acid contained in the buffer is able to penetrate those membranes. Another method involves using cationic polymers, such as DEAE dextran, to mediate nucleic acid entry and expression in cultured cells. Another method employs ballistic delivery of nucleic acid into cells. Finally, microinjection of nucleic acid can be used.

Large numbers of identical vectors (e.g., expression vectors containing library sequences) can be introduced into each animal cell by fusing such cells with spheroplasts of bacteria harboring a multi-copy vector. The fusion is performed in a manner that on the average allows for the fusion of one spheroplast with one animal cell. For example, when a high copy number plasmid, such as a derivative of a pUC plasmid, is used, many identical plasmids are typically introduced into each animal cell. This method circumvents the need for amplification of the vector in animal host cells, and allows for high copy number in the host cells and the resulting high levels of expression of library sequences. This procedure can also provide for longer periods of transient expression without a need to amplify the vectors in animal host cells. High copy numbers of vector also increase the ease with which library sequences can be recovered from animal host cells which exhibit a change in reporter expression.

In some of these methods, multiple nucleic acids which can encode polypeptides which might interact with a target molecule are introduced into individual cells. Methods are known in the art to minimize transfer of multiple fragments. For example, by using "carrier" nucleic acid (e.g., DNA such as salmon or herring sperm

DNA, tRNA, and the like), or by reducing the total amount of nucleic acid applied to the host cells, the problem of multiple fragment entry can be reduced. In addition, each recipient cell can receive multiple nucleic acid fragments. Multiple passages of the library through the host cells permit sequences of interest to be separated ultimately from other sequences that can be present initially as false positives.

In a preferred embodiment, retroviral vectors introduce one peptide sequence into each cell. This supplies a robust signal and reduces the dilution effect on a signal from multiple expression vectors in any given cell.

#### 10 Host Cells Displaying Peptides

In an exemplary embodiment, peptides, encoded by oligonucleotides comprising an expression library, are displayed within the secretory pathways and extracellular surfaces of host cells into which the expression library has been introduced. Host cells transfected with expression library sequences will co-express the membrane protein of interest with peptide molecules, passing simultaneously through the secretory pathway with the effector peptide, and being also tethered to the cell surface along with the membrane protein. Thus, the expressed peptides will be present with the membrane protein molecules during processing and, therefore, these peptides will be available to interact with the membrane protein of interest, the processing enzymes of the membrane protein, or other macromolecules that are involved in processing of the membrane protein. Further, during transience through secretory pathways, the library peptides will be expressed under physiological conditions native to the processing of the membrane protein. Similarly, where the extracellular environment of the host cells is maintained under substantially physiological conditions, library peptides on the extracellular surface will also be expressed under conditions that preserve or approximate those native to membrane protein processing in the extracellular environment.

The peptides are typically displayed under substantially physiological conditions on the surface of host cells, such as mammalian cells. Each host cell can express on its surface hundreds and possibly thousands of copies of one or more library peptides, a majority of which are typically available for binding to extracellular membrane protein target molecules. The peptides are typically present on the surface of a cell for a sustained period of time.

In certain embodiments, the host cells expressing the peptide libraries are freshly prepared or live cells. In other embodiments, the peptide library expressing cells

can be fixed, such as in para-formaldehyde or other suitable fixative. Such fixed peptide library-expressing cells optionally can be stored at a suitable temperature (*e.g.*, 4°C) until use. The peptides are typically presented on the surface of the cells for a sustained period of time.

5                   In some embodiments, host cells transfected with an expression library are enriched for cells that contain the expression vector and optimally expressing a library peptide. Such selection is typically based on selectable markers contained within the library expression vector (*see* Expression Cassettes and Vectors). Methods for selection using selectable markers are known in the art. For example, FACS can be used detect  
10 fluorescently labeled antibodies to epitopes encoded by the expression vector (*e.g.*, V5, FLAG, thioredoxin, and the like) or to the presentation molecule itself (*e.g.*, CD24). In addition, magnetic bead selection can be used by known methods.

#### Prescreening of Agents for Agents That Specifically Bind to the Membrane Protein

15                   In certain embodiments, compound libraries and expression libraries can be prescreened to identify agents that specifically bind to the membrane protein of interest. Prescreening can be performed, for example, under substantially physiological conditions. Agents identified as specifically binding to the membrane protein of interest, or a functional fragment thereof, can be used to generate a compound or expression library  
20 enriched for membrane protein-binding agents ("pre-enriched compound library" or "pre-enriched expression library"). In one embodiment, enrichment can be accomplished by expressing the external domain of APP (edAPP) with an affinity tag (such as a His tag), binding the edAPP to a column, passing compound libraries over the column, and eluting the enriched compounds from the column. The enriched compounds can then be tested on  
25 the host cells.

                  Further, in certain embodiments, N-terminal truncated forms of APP are used to prescreen agents for specific binding to APP. These truncated forms have the advantage of being a more specific target for peptide enrichment. The utility of using the truncated forms is underscored specific target for peptide enrichment. The utility of using  
30 the truncated forms is underscored by the fact that the  $\alpha$  and  $\beta$  cleavage sites are not significantly affected by removal of most of the N-terminal sequence APP (*see* De Stoooper *et al.*, *J. Biol. Chem.* 270:30310-30314, 1995; Lammich *et al.*, *Proc. Natl. Acad. Sci. USA* 96:3922-3927, 1999).

                  In an exemplary embodiment of the invention, the peptide expression

libraries are prescreened to identify oligonucleotides encoding peptides that specifically bind to the membrane protein of interest or a functional fragment thereof. Those clones identified as encoding membrane protein-binding peptides can be recovered and amplified using methods known in the art to produce a pre-enriched expression library. This pre-enriched expression library comprises a population of oligonucleotide sequences enriched for those that encode peptides that bind to the membrane protein of interest. The enriched library of oligonucleotide sequences can then be introduced into host cells according to the methods of the present invention to identify those membrane protein-binding peptides that alter processing of the membrane protein of interest.

For example, using methods known in the art, the expression library can be introduced into an animal host cell for expression or, alternatively, expressed using a non-animal system such as, *e.g.*, phage display. The expressed peptides can then be contacted with labeled membrane protein and/or N-terminal truncated forms of the membrane protein of interest, either soluble forms (*e.g.*, the extracellular domain of the membrane protein or a N-terminal truncated form) or expressed on the surface of animal host cells. Suitable labels include, for example, radioactive labels (*e.g.*,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and the like), fluorescent molecules (*e.g.*, fluorescein isothiocyanate (FITC), rhodamine, phycoerythrin (PE), phycocyanin, allophycocyanin, ortho-phthaldehyde, fluorescamine, peridinin-chlorophyll a (PerCP), Cy3 (indocarbocyanine), Cy5 (indodicarbocyanine), lanthanide phosphors, and the like), enzymes (*e.g.*, horseradish peroxidase,  $\beta$ -galactosidase, luciferase, alkaline phosphatase), biotinyl groups, tag epitopes as described above, and the like. In some embodiments, detectable labels are attached by spacer arms of various lengths to reduce potential steric hindrance. Alternatively, labeled binding partners, such as, for example, antibodies that bind to the target molecules can be used. In one exemplary embodiment, the APP molecules are labeled with a His tag epitope label.

The expressed peptides that bind to the membrane protein of interest or one of the truncated forms thereof can then be identified using the label and methods known in the art. For example, phage or cells expressing peptides and exposed to His tag extracellular domain the membrane protein can be passed over a His tag affinity column to enrich for those phage or cells expressing the membrane protein-binding peptides. Alternatively, for example, peptide-expressing animal cells can be exposed to fluorescently tagged extracellular membrane protein or a truncated for the membrane protein and membrane protein-binding cells can be identified and sorted by FACS to

obtain cells expressing the peptides that specifically bind to the membrane protein of interest. Multiple rounds of such enrichment can be performed.

After enrichment of cells or phage expressing membrane protein-binding peptides, the peptide encoding sequences can be excised from the expression vector used for pre-enrichment and transferred, using known methods, to an appropriate vector (*see* Expression Cassettes and Vectors, *infra*) for screening for those membrane protein-binding peptides that alter processing of the membrane protein. In some embodiments of the invention, where animal host cells are used for pre-enrichment, the expression vector used for the screening of peptides that alter processing of the membrane protein can be the same as used for peptide expression during pre-screening.

#### Detection of Agents That Alter Processing of the Membrane Protein

In another aspect, the effect of agents within the compound or expression libraries on membrane protein processing is assayed. The host cells expressing the membrane protein of interest, *e.g.*, TGF- $\alpha$ , TNF- $\alpha$ , APP, TNFR, and the like, and at least one processing enzyme, *e.g.*, TGF- $\alpha$  secretase, TNF- $\alpha$  secretase,  $\alpha$ -secretase,  $\beta$ -secretase, or  $\gamma$ -secretase, and TNFR secretase respectively, are contacted with the agents and the host cells are then assayed for an effect on the processing of membrane protein expressed by the host cell. In some embodiments, the host cells are contacted with the agents under substantially physiological conditions. In an exemplary embodiment, the effect on APP processing of peptides comprising a peptide expression library is assayed, the expression library having been introduced into the host cells (*see* Genetic Libraries, Expression Cassettes and Vectors, Nucleic Acid Transfer, and Host Cells Displaying Peptides, *supra*). In another embodiment, an extract from, for example, a plant, *e.g.*, a peat extract, comprising an agent of the present invention is admixed with the host cells for a sufficient time period to detect an effect.

Effects of agents within the libraries on membrane protein processing can be detected by any suitable detection means, such as, for example, the use of markers that specifically bind to particular fragments of the membrane protein. In the specific example of APP the fragments can be, for example, APPs- $\alpha$ , APPs- $\beta$ , APPs- $\gamma$ . In the examples of TGF- $\alpha$ , TNF- $\alpha$  and TNFR marker that bind specifically to the soluble forms of the membrane proteins can be used. Using such markers, the relative presence or absence of a particular membrane protein fragment that correlates with processing, in comparison to host cells that have not been contacted with agents or that do not express library peptide

sequences, can be determined. For example, membrane protein fragment specific binding markers can be labeled with fluorescent tags and the host cells assessed for the relative presence or absence of such marker by known methods such as, *e.g.*, (FACS) analysis. In an exemplary embodiment, the markers are antibodies specific for particular epitopes of the membrane protein or membrane protein fragments. Antibodies to particular APP fragments, including APPs- $\beta$  (such as, for example, A3 or 1G7 specific to APP midregion, Koo *et al.*, *J. Biol. Chem.* 269:17386-17389, 1994), APPs- $\alpha$  (6E10 specific to the carboxy terminal end of APPs- $\alpha$  or the region of APP between the  $\beta$  and  $\alpha$  cleavage sites, Pirttila *et al.*, *Neurol Sci.* 127:90-95, 1994, McLaurin *et al.*, *Nature Med.* 8:1263-1269, 2002, and p3 (4G8, Pirttila *et al.*, *Neurol Sci.* 127:90-95, 1994, McLaurin *et al.*, *Nature Med.* 8:1263-1269, 2002).

In an exemplary embodiment, where the host cells express more than one membrane protein processing enzyme, the ratio of detection signals of at least two labeled markers specific for at least two different membrane protein fragments can be determined. For example, altered APP processing can be determined by detecting a change in this ratio in host cells expressing library sequences. In host cells expressing both  $\alpha$ - and  $\beta$ -secretase, antibodies specific for APPs- $\alpha$  and APPs- $\beta$  can be labeled with two different fluorescent tags (*e.g.*, FITC and PE) and the presence of bound, labeled antibody determined by FACS. Host cells expressing library peptides can then be selected according to an increase in APPs- $\beta$ :APPs- $\alpha$  signal ratio, indicating a reduction in the  $\beta$ -secretase processing.

In some embodiments, agents identified as having an effect on the processing of the membrane protein can be used to build a sub-library enriched for agents that affect processing. This sub-library can then be contacted with host cells in subsequent rounds of screening to identify agents with the desired characteristics (*see* Characterization of Library Constituents, *infra*).

In an exemplary embodiment, host cells expressing a peptide library that are isolated or collected by any of the methods described herein can be used to re-isolate the genetic library sequences(s) so as to build a sub-library of sequences enriched for those that affect processing. As will be appreciated by those skilled in the art, such sequences can be isolated by, among other methods, recovering expression vector nucleic acids from the selected clones and transforming them into a suitable bacterial host strain, by cloning the library oligonucleotides by PCR using any suitable priming site(s) that flanks the

oligonucleotide inserts, by subcloning the oligonucleotides from the original expression vector into another vector, and the like. The sub-library of oligonucleotides optionally can be recloned into an expression cassette or vector, as necessary, and reintroduced into the host cells for subsequent rounds of screening. Screening/selection cycles can be repeated  
5 as many times as necessary.

In certain embodiments, after a sufficient number of cycles, a substantial difference is observed in the assay signals or ratios thereof, indicating changes in the presence of fragments of the membrane protein between an enriched sub-library of peptide sequences and the original peptide library (*e.g.*, in an intensity distribution). By the  
10 process of sequential introduction of the expression library, or portions thereof, sorting in a flow sorter or similar device and isolation of nucleic acids from host cells exhibiting the desired assay results, a population of library oligonucleotides can be identified that encode the desired peptide(s). The oligonucleotides can then be isolated and studied individually by molecular cloning and nucleic acid sequence analysis. If a sufficient number of cycles  
15 have been carried out, many, and typically most, separate oligonucleotides should encode a peptide that produces about the same effect binding event when expressed on host cells.

#### Identification of Allosteric Effectors

In certain embodiments, effector agents can be assayed to identify allosteric  
20 effectors of the membrane protein of interest. Identification of allosteric effectors can be performed as a secondary screen on agents that have been identified as effectors of membrane protein processing. Alternatively, compound libraries or peptide expression libraries can be prescreened to identify agents that bind to a potential allosteric site on the membrane protein. Prescreens comprise detecting a conformational change in the  
25 membrane protein bound to the agent. The identification of allosteric effectors can be done directly using a cellular assay where effectors of secretase, the membrane protein, *e.g.*, APP (allosteric), and any other interaction that causes differential processing at any of the processing sites are identified. Those that cause differential processing by binding to the membrane protein can be identified from this group. In addition, by prescreening for  
30 membrane protein binding compounds and then screening with the cell based assay, the system is predisposed to the identification of allosteric effectors of the membrane protein.

#### Characterization of Library Constituents

Effector agents identified using any of the procedures described herein can

be further characterized. Where expression libraries are used to display peptides within secretory pathways and on the extracellular surface of host cells, library sequences can be isolated from host cells by any suitable method, such as, for example, HIRT lysis and recovery of vectors in bacterial host cells, polymerase chain reaction, and the like. (See, 5 *e.g.*, Hirt, *J. Mol. Biol.* 26:365-369, 1967; U.S. Patent Nos. 4,683,202, 4,683,195 and 4,800,159; Innis *et al.*, *PCR Protocols: A Guide to Methods and Applications*, Academic Press, Inc., San Diego, CA (1989); Innis *et al.*, *PCR Applications: Protocols for Functional Genomics*, Academic Press, Inc., San Diego, CA (1999); White (ed.), *PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering*, Humana Press, 10 (1996); EP 320 308; Ausubel *et al.*, *supra*; Sambrook *et al.*, *supra*; which are incorporated by reference herein in their entirety.)

Subsequent rounds of screening optionally can be performed to enrich for agents that alter processing of the membrane protein. Sub-libraries of compound or 15 expression libraries can be passed through additional screens and/or selections to enrich for those agents or oligonucleotide sequences that have more desirable properties. To enrich for effector agents that have more favored properties, it can be desirable to passage a sub-library (that has been isolated by any of the methods described above) through additional screens to enrich for those agents with, for example, improved specificity or 20 avidity for the membrane protein or with an increased effect on processing of the membrane protein. For instance, minor effects on an undesirable secretory or extracellular interaction can be eliminated by appropriate secondary screens. If desired, additional labels can be used to identify library peptide sequences that affect secretory or extracellular molecular interactions. In addition, effector agents that have generalized, 25 non-specific effects on secretory or extracellular interactions can be identified by contacting compound sub-libraries or individual effector agents with (or passing expression sub-libraries or individual library peptide sequences through) different host cells that lack the membrane protein or membrane protein processing enzyme expression and then conducting screens on those cells that assay for processing alterations or other 30 effects on other, non-membrane protein secretory or cell-surface molecules.

In some cases, effector agents identified according to the present invention can be used to identify other agents that alter processing of the membrane protein. For example, small organic molecules identified as molecular effectors of membrane protein processing can be used in directed-screening approaches to identify agents with improved

characteristics, including, *e.g.*, reduced toxicity or increased efficacy. For example, modifications can be made to one or more subunits comprising the effector agent. Modifications can include variation as to type, number, or position of R groups. Modified small molecule effector agents can then be screened using the methods described herein  
5 for agents with the improved characteristics.

Further, where peptide libraries are used, including peptide expression libraries, peptide or oligonucleotide sequences can be modified. In some cases, an original library may not contain all possible permutations of an amino acid sequence of length N (*e.g.*, when the original library is a semi-random library). In such cases, it can be possible  
10 to isolate and use the identified peptides as a starting material ("lead compound") to identify additional peptides or peptides with enhanced function (*e.g.*, higher avidity or affinity) as compared with the original peptide. To isolate variants of a library sequences, amplification of nucleic acids (*e.g.* by polymerase chain reaction) can be used to introduce sequence changes during the replication process. (*See, e.g., Cline et al., Nucleic Acids*  
15 *Res.* 24:3546-3551, 1996). Such mutations can lead to sequence variants that have more effective properties. Alternatively, it can be desirable to seek improved variants of existing sequences by deliberately subjecting the amplification process to conditions that enhance mutation and/or recombination of the nucleic acid(s), such as by, for example, *in vitro* mutagenesis, error-prone PCR and/or recombinational PCR. (*See, e.g., Ausubel et al., supra; Stemmer, Nature* 370:389-391, 1994). Such conditions are known in the art and provide a means for searching for sequences that are active at lower concentrations and/or that demonstrate increased specificity and/or activity compared to the sequences expressed by the original library.

## 25 Applications of the Molecular Effectors of Membrane Protein Processing

The methods according to the present invention provide the ability to identify physiologically relevant effector agents that bind and alter the processing of the membrane protein, particularly under physiological conditions.

Effector agents identified using the methods described herein for APP  
30 processing can be tested in, *e.g.*, a transgenic mouse model, such as, for example, Tg (HuAPP695.K670N/M671L) (Hasio *et al., Science* 274:99-102, 1996) or the PDAPP (V171F) (Games *et al., Nature* 373:523-527, 1995), to study their efficacy in plaque inhibition and capacity to reduce A $\beta$  levels in CSF, brain cells, and serum. Effector agents

can be administered by injection or orally. In addition, where the effector agent is a peptide, the identified peptide can be also be tested by expressing the peptide in the mouse model. The, identified effector peptides can also be expressed and presented extracellularly or expressed and secreted in specific tissues. Other transgenic and non-  
5 transgenic animal models are well known in the art for other secreted proteins of the present invention that can be used to test the effectors identified by the methods disclosed herein.

#### Additional Modifications to Enhance Function of Peptide Effectors

10 As discussed previously, peptide sequences that affect differential processing of the membrane protein can exert their effect in a variety of ways. As will be appreciated by those skilled in the art, it can be possible to improve the effectiveness of a peptide by synthesizing peptide variants or analogs. For example, the effectiveness of peptides might be improved by administering the peptides themselves (*i.e.*, without any  
15 extra sequences).

One skilled in the art will appreciate that structural analogs and derivatives of peptides (*e.g.*, peptides having conservative amino acid insertions, deletions or substitutions, peptidomimetics, disulphide cross-linking, artificial cross-linking, or the like) can also be useful as therapeutic agents. For example, in addition to the above-  
20 described peptides, which can comprise naturally-occurring amino acids, peptide analogs can be used as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compounds can be developed, for example, with the aid of computerized molecular modeling. (*See, e.g.*, Fauchere, *Adv. Drug Res.* 15:29, 1986; Veber and Freidinger, *TINS* 392, 1985; Evans *et al.*, *J. Med. Chem.* 30:1229, 1987).  
25 Such analogs, or peptide mimetics, are structurally similar to therapeutically or prophylactically useful peptides and can be used to produce an equivalent therapeutic or prophylactic effect. In some cases, peptide mimetics can have significant advantages over peptides, including, for example, more economical production, greater chemical stability, enhanced pharmacological properties (*e.g.*, half-life, absorption, potency, efficacy, and the  
30 like), altered specificity (*e.g.*, a broad-spectrum of biological activities), increased, reduced antigenicity, increased passage over the blood brain barrier, and other desired properties.

Peptide mimetics can be generated by methods known in the art and further described in the following references: Spatola, *Chemistry and Biochemistry of Amino*

*Acids, Peptides, and Proteins* (Weinstein, ed.) 267, 1983; Spatola, *Vega Data*, Vol. 1, Issue 3, "Peptide Backbone Modifications" (March 1983); Morley, *Trends Pharm Sci.*, pp. 463-468, 1980; Hudson *et al.*, *Int. J. Pept. Prot. Res.* 14:177-185, 1979; Spatola *et al.*, *Life Sci.* 38:1243-1249, 1986; Hann, *J. Chem. Soc. Perkin Trans. I*, pp. 307-314, 1982;

5 Alnquist *et al.*, *J. Med. Chem.* 23: 1392-1398, 1980; Jennings-White *et al.*, *Tetrahedron Lett.* 23:2533, 1982; European Patent Application EP 45665, 1982; Chemical Abstract 97:39405, 1982; Holladay *et al.*, *Tetrahedron Lett.* 24:4401-4404, 1983; and Hruby, *Life Sci.* 31:189-199, 1982.

In one aspect, pharmaceutically acceptable salts of a peptide (or analog or  
10 mimetic) can be readily prepared by conventional methods. For example, such a salt can be prepared by treating the peptide with an aqueous solution of the desired pharmaceutically acceptable metallic hydroxide or other metallic base and then evaporating the resulting solution to dryness, typically under reduced pressure in a nitrogen atmosphere. Alternatively, a solution of a peptide can be mixed with an alkoxide  
15 of the desired metal, and the solution subsequently evaporated to dryness. The pharmaceutically acceptable hydroxides, bases, and alkoxides encompass those with cations for this purpose, including, but not limited to, potassium, sodium, ammonium, calcium, and magnesium. Other representative pharmaceutically acceptable salts include hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate,  
20 borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and the like.

It can be desirable to stabilize the peptides or their analogs or derivatives to increase their shelf-life and pharmacokinetic half-life. Shelf-life stability can be improved by adding excipients such as: a) hydrophobic agents (*e.g.*, glycerol); b) sugars (*e.g.*,  
25 sucrose, mannose, sorbitol, rhamnose, or xylose); c) complex carbohydrates (*e.g.*, lactose); and/or d) bacteriostatic agents. The pharmacokinetic half-life of the peptides can be modified by coupling to carrier peptides, polypeptides, and carbohydrates using chemical derivatization (*e.g.*, by coupling side chain or N- or C-terminal residues), or by chemically altering an amino acid of the subject peptide. The pharmacokinetic half-life and  
30 pharmacodynamics of these peptides can also be modified by: a) encapsulation (*e.g.*, in liposomes); b) controlling the degree of hydration (*e.g.*, by controlling the extent and type of glycosylation of the peptide); c) controlling the electrostatic charge and hydrophobicity of the peptide, and d) formulation in a pharmaceutically acceptable depots such as polyactic acid, polyglycolic acid, poly lactic-co-glycolic acid, or the like.

### Examples

The following examples are provided merely as illustrative of various aspects of the invention and should not be construed to limit the invention in any way.

5

#### Example 1: Preparation of a Genetic Library in a Host Cell

A genetic library is prepared by inserting random oligonucleotides into a cloning site of an expression vector. The expression vector has an expression cassette comprising, in a 5' direction relative to the direction of transcription, a promoter, a nucleic acid encoding a signal sequence, a nucleic acid encoding a presentation molecule, a cloning site located at the 5' end of the nucleic acid encoding the presentation molecule, a nucleic acid encoding a transmembrane domain, and a transcription terminator. The expression vector includes an origin of replication (*ColEI*) and an antibiotic resistance marker for selection in *E. coli*. The random oligonucleotides encode peptides of about 7 to about 20 amino acid residues. The vectors containing the oligonucleotides are transformed into host bacteria and grown under selectable conditions to establish a library of about 10 million to several billion independent isolates. Vector DNA is prepared from this library. This vector DNA is introduced into animal cells, such as, for example, human cells, mammalian cells, or other animal cells.

15  
20

#### Example 2: Engineering the Random Peptide Vector for the Expression of APP Effectors

The preferred random peptide vector for the expression of APP effectors is a retroviral vector with the cassette insert shown in the Figure 3. The cassette encodes a promoter; a secretory sequence to cause the protein to enter the secretory pathway; a random peptide sequence encoding cysteines at the termini of the random sequence to cause disulfide bridge formation lending structure to the random amino acid sequence; a glycine spacer; a presentation protein; a second glycine spacer to impart flexibility at the cell surface; and a GPI linker sequence that causes the fusion protein to be tethered to the cell surface. The presentation protein is a globular inert protein on which the random peptide sequence is tethered and displayed. This configuration allows the peptide ring of random amino acids to be tethered at the end of a string of glycines providing flexibility. The glycine spacer between the cell and the presentation protein also allows for flexibility of the whole tethered molecule. Flexibility for the peptide ring minimizes steric hindrance from the presentation protein with the binding of the random amino acid sequence to APP.

25  
30

### Example 3: Expression Vector Construction

To achieve high expression levels of library peptides on the surface of host cells, an expression vector is used. The expression vector includes markers required for propagation and selection in bacteria, an expression cassette including a mammalian cell transcription promoter (*e.g.*, the cytomegalovirus or EF-1 $\alpha$  promoter, and the like), a nucleic acid encoding a presentation molecule and a transcription terminator. Random library sequences can be inserted at the N-terminus, at the C-terminus, or internally in the nucleic acid encoding the presentation molecule and can be in a linear or constrained loop array or in an exposed loop of the presentation molecule.

To attach the presentation molecule to the surface of host cells, the nucleic acid encoding the presentation molecule includes a sequence encoding a secretory signal sequence and an element to tether the fusion protein to the cell surface (*e.g.*, a signal for glycosylphosphatidylinositol (GPI) anchorage or a transmembrane and intracellular domain). Suitable presentation molecules include, for example, the IL-3 receptor, protein A thioredoxin, CD4, CD20, or CD24. The presentation molecule can also include one or more epitopes, such as, for example, FLAG, V5 or polyhistidine. The transcription terminator, can be, for example, from human growth hormone.

Two distinct expression vectors were constructed to display peptide libraries on the surface of cells of mammalian cells such as COS7 and K562 cells. One construct places the peptides, having 7 amino acid residues, at the N-terminus as a linear structure, while the other construct includes a cysteine residue at each end of the peptide sequences to form a constrained loop at the N-terminus. Each construct encodes a presentation molecule including thioredoxin, the V5 or FLAG epitopes, the secretory signal sequence from CD24 for secretion, and the GPI linkage sequence from CD24 for attachment to the surface of the host cell. The approximate diversity of each of the completed peptide expression vectors is about  $1 \times 10^9$  unique peptides, although libraries of considerably greater diversity can be produced.

### Example 4: Establishment of Assay Cell Lines for the Identification of APP Effectors

There are four primary requirements for the assay cell line to identify effectors of APP: 1) the cells must possess the natural complement of APP processing enzymes, 2) the cells must constitutively produce APP, 3) the cells are suspension cells to

facilitate the high throughput requirement of these experiments, and 4) the screening system needs to mimic the natural physiological conditions associated with APP expression.

APP expressing cell lines are prepared by constructing a mammalian  
5 expression vector encoding APP and introducing this expression vector into the parent cell line. Two cell lines, a neuroblastoma cell line and a human embryonic kidney cell line (HEK), are preferred for these experimentations. Both of these cell lines have been used in APP experimentation (Cedazo-Minguez *et al.*, *Neurochem. Int.* 35:307-315, 1999; Lopez-Perez *et al.*, *J. Neurochem.* 73:2056-2062, 1999). The HEK cell line is easier to  
10 grow and presents fewer challenges than the neuroblastoma cell line and therefore is preferred for these experiments. The neuroblastoma cell line is an alternative cell line.

To facilitate these experiments, the HEK cells are adapted to spinner culture conditions. Adaptation is accomplished by gradually reducing the amount of serum in the culture medium in static cultures until the cells are capable of growing in  
15 serum free media. The cells are then transferred and grown in spinner culture vessels. There is significant cell death with both of these procedures but some cells survive and grow. The cells that grow the best under these conditions outgrow cells that grow less well, producing cells adapted to grow well under serum free spinner culture conditions. These procedures will be understood by someone skilled in this art.

20 The cDNA encoding APP may be obtained from ATCC or IMAT or alternatively obtained by PCR amplification and verified by DNA sequence analysis. The APP encoding cDNA is inserted into a mammalian expression vector and electroporated into the parental mammalian cell line. The electroporated cells are plated in microtiter plates at a density to allow for cell growth in 50 % of the wells under neomycin selection,  
25 to provide conditions allowing for clonal isolation. These cell lines are assessed for APP expression by fluorescent microscopy and FACS analysis using anti-APP antibodies as described below.

To successfully implement a screening strategy as described in this application, it is important to be able to manipulate and screen large numbers of cells and  
30 peptide sequences. By utilizing suspension culture cells and spinner culture vessels, methods of growing, handling, and utilizing billions of cells per day can be implemented.

### Example 5: *In Vitro* Expression of APP and Analysis of Products

Clones of wild type APP and APP containing the Swedish, Arctic, and/or Dutch mutations were expressed in HEK-293 cells. Expression of the mutant clones are  
5 useful as controls to show differences in processing in an *in vitro* screening assay  
screening assay for effectors of APP processing.

To construct the expression plasmids, a clone encoding the full-length wild  
type 695 amino acid human APP (Kang *et al.*, *Nature*, 325:733-736, 1987) was obtained.  
A 3kb fragment from the *NruI* site in exon 1 to the *SmaI* in the 3'UTR was subcloned into  
10 the pcDNA3.1 vector. This vector contains a CMV promoter and an SV40  
polyadenylation sequence. Similarly, clones encoding APP<sub>Swe</sub> and APP<sub>Arc</sub> were used as  
starting material for the construction of CMV-APP<sub>Swe</sub> and CMV-APP<sub>SweArc</sub>.  
These constructs were introduced into HEK-293 cells. Cleavage by endogenous  
secretases results in processing of the APP protein into several fragments. APP protein  
15 expression and processing was assessed by Western blot analysis of lysates and  
conditioned media of mock-transfected (*i.e.*, transfected with a plasmid lacking the APP  
sequence) and APP<sub>Swe</sub>-transfected cells. Full-length APP as well as C-terminal fragment  
C99, A $\beta$ , APPs- $\alpha$ , and APPs- $\beta$  were detected using 6E10 antibody, which recognizes  
amino acids 1–16 of A $\beta$  sequence. Full-length APP, C99, and A $\beta$  were found in cell  
20 lysates from APP<sub>Swe</sub> transfectants. The identification of A $\beta$  in the cell lysate is believed to  
be the result of processing within the secretory pathway. APPs- $\alpha$  and A $\beta$  were detected in  
conditioned medium from APP<sub>Swe</sub> transfectants. APPs- $\alpha$  and APPs- $\beta$  were also detected  
in conditioned medium of cells transfected with the Swedish or Swedish/Arctic mutation  
using 6E10 antibody and Sw192 antibody, respectively. Antibody Sw192 (Elan  
25 Pharmaceuticals) recognizes the amino acids 590-596 of APP<sub>Swe</sub> only when it has been  
cleaved by  $\beta$ -secretase.

### Example 6: Retroviral Infection

The retroviral expression vector is packaged in a packing cell line (Miller *et*  
30 *al.*, *Methods Enzymol.* 217:581-599, 1993) and utilized to infect the assay cells containing  
secretase processing enzymes and APP. The fusion protein will enter and pass through the  
secretory pathway under the influence of the secretory signal concluding with presentation

on the cell surface. At the cell surface, the fusion protein comprising the presentation protein, glycine spacers and random amino acid sequence (display complex) becomes attached to the cell via the GPI linkage. Processing of APP by some of the secretases appears to occur during transience through the secretory pathway as well as at the cell surface (Selkoe, *Physiological Rev.* 81:741-767, 2001). The display complex and APP will similarly pass through the secretory pathway and be displayed on the surface of the cell in a common process. Therefore, the random amino acid sequence will be present and the effective peptide will have the opportunity to bind to APP altering its structure within the secretory pathway as well as at the cell surface. Figure 4 depicts the configuration of the display complex.

#### Example 7: Enrichment of Transfected Cells

Cells vary in the efficiency to take up DNA and express it. In cases where introduction of expressible DNA is not very efficient, it can optionally be possible to enrich for cells that contain the expression vector (*e.g.*, plasmid) and are optimally expressing the DNA. To allow enrichment of cells that contain the genetic library, a label, such as a sequence encoding a marker, is included in the expression vector. Such a marker typically will remain attached to the cell. This sequence encoding the marker can be, for example, a transcription promoter and terminator, a sequence encoding a secretory signal sequence (*e.g.*, CD24), one or more extracellular domains (*e.g.*, V5, FLAG, and the like) and a sequence to tether the marker to the cell surface (*e.g.*, a signal for glycosylphosphatidylinositol (GPI) anchorage). The placement of peptide libraries between two distinct markers (*e.g.*, V5 and FLAG) can ensure the integrity of the peptide library by selecting only cells that contain both markers in the presentation molecule and that are expressed on the surface of host cells.

The expression vectors described in Example 3 have been used to transfect COS7 cells by electroporation employing conditions to introduce, on average, only one or a few vectors per cell. The cells were placed in culture following transfection and analyzed at various times by FACS to detect the expression of thioredoxin or FLAG on the surface or interior of cells. In each case, a relatively high percentage of cells express the presentation molecules (*e.g.*, thioredoxin - detected using anti-thioredoxin antibody) one day post-transfection, and the molecules persisted over the next week. These results indicate that presentation molecules are expressed at relatively high levels over several days.

Transfected host cell, expressing a peptide library were also fixed in para-formaldehyde prior to FACS analysis or selection on magnetic beads. The results demonstrated that the marker epitopes were still accessible to antibody following fixation, indicating that the library peptides were available for binding to target molecules.

5 Similar experiments demonstrated that K562 cells, transfected by electroporation with plasmid vectors encoding a peptide library, were transfected at approximately 50% efficiency with 80% cell survival. The optimum expression period was between one and two days following transfection. The level of expressed presentation molecule on K562 cells was lower than that on COS7 cells, because K562 cells do not  
10 amplify the plasmid vectors as do COS7 cells. However, sufficient presentation molecules were expressed on the surface of K562 cells as demonstrated by localization of labeled anti-FLAG antibody.

The results demonstrate a robust system for displaying peptide libraries on the surface of mammalian cells. The tethering of the presentation molecule via a GPI  
15 linkage to the cell and the use of domains from thioredoxin and CD24 lead to the persistent, stable expression of peptide libraries. Further, the placement of the peptides at the N-terminus of the presentation molecule ensures unobstructed accessibility of the peptides to potential target molecules, relatively distant from the cell surface and in a highly favorable hydrophilic environment.

20

#### Example 8: Prescreening for Peptides that Bind APP

Because of the interest in peptide structures that bind and alter the structure of APP, and because not every peptide that binds to APP will modulate proteolytic processing of the protein, however, all peptides that affect processing can be expected to  
25 have a high affinity binding for APP, a pre-enrichment of peptides that simply bind APP is performed. Phage display is used for this enrichment process because of the large number of structures that may be generated and screened by this method. The APP extracellular domain and two N-terminal truncated forms, one beginning at nucleotide 457 just 3' to the Kunitz protease inhibitor domain sequence and the second at nucleotide 550 are expressed  
30 in bacteria and CHO-DG44 cells with a His tag for easy purification. The production, stability, and ease of purification of these affinity molecules determine the affinity molecule of choice.

Phage expressing random peptide sequence are exposed to His tag

extracellular domain APPs and passed over a His affinity column. After 2 or 3 rounds of enrichment the nucleotide sequences encoding the random peptides are excised from the DNA of enriched phage and transferred to the retroviral vector. This enrichment step increases the probability of identification of a peptide that alters APP processing by  
5 binding to APP rather than altering the activity of the processing enzymes or causing a change in processing in some other manner.

#### Example 9: Screening for Effector Peptides

Assay cells are grown in large numbers, approximately a billion or more. The cells are infected with retrovirus encoding a peptide library. After two days of  
10 growth, the cells are selected by magnetic bead selection for those cells expressing the display complex utilizing biotinylated anti-presentation protein antibody and streptavidin coated beads (Miltenyi Biotec, Germany). Selection enriches for cells expressing the display complex on the surface of cells. This eliminates cells that are not infected and cells expressing a sequence that is prematurely terminated by a stop codon in the random  
15 DNA sequence. Semi-random DNA encoding the random peptide sequence is used to minimize stop codons but does not completely eliminate it (LaBean and Kauffman, *Protein Sci.* 2:1249-1254, 1993). The frequency of stop codons is related to the length of the random peptide sequence. An amino acid length of about 7 to about 12, or about 16 will typically be used.

20 Magnetic bead selection also eliminates cells that have been infected, have the capacity to synthesize full length tethered display complex, but do not express sufficient amounts of the display complex due to, for example, integration into a silent expression site in the chromosome. Selection therefore provides cells that are expressing sufficient levels of display protein to be effective in altering the structure of APP. The  
25 validity of this configuration has been demonstrated by expressing tethered effector peptide sequence in growth dependent Ba-F3 cells expressing thrombopoietin receptor. The tethered effector peptide confers growth independence to the previously growth dependent cell line. This demonstrates that a tethered peptide can alter the structure of a cell surface receptor causing activation of the receptor and cell survival.

30 Bead enriched cells are sorted by fluorescent activated cell sorting (FACS) utilizing differentially labeled antibodies recognizing different fragments of APP. To

enrich for peptides causing increased  $\alpha$ -secretase processing, sorting will be performed based on a change in the ratio of fluorescence between PE labeled antibody (6E10, Pirttila *et al.*, *Neurol. Sci.* 127:90-95, 1994, McLaurin *et al.*, *Nat. Med.* 8:1263-1269, 2002) recognizing amino acid 3-10 in A $\beta$  corresponding to the C-terminal end of APPs- $\alpha$  and  
5 FITC labeled anti-p3 antibody (4G8, Pirttila *et al.*, *Neurol. Sci.* 127:90-95, 1994, McLaurin *et al.*, *Nature Med.* 8:1263-1269, 2002) recognizing amino acid 16-24 of A $\beta$ , corresponding to the N-terminal end of p3 (See Figure 5). Control cells infected with the expression vector without random peptide sequence provide a control PE/FITC ratio. Cells with a lowered PE/FITC fluorescent ratio are collected.

10 Similarly, cells are sorted for peptides causing a reduction in  $\beta$ -secretase processing by collecting cells with increased ratio of FITC labeled anti-APP- $\beta$  (A3 or 1G7 specific to APP midregion, Koo *et al.*, *J.Biol.Chem.* 269:17386-17389, 1994) to PE labeled antibody (6E10) anti-APPs- $\alpha$  fluorescence (See Figure 5).

To set up and test the APP effector assay system, reagents and conditions  
15 are used that influence the amount of cleavage at the  $\alpha$  and  $\beta$  sites to demonstrate the sensitivity and validity of the assay. For example, assay cells are transfected with expression vectors encoding either  $\alpha$  or  $\beta$ -secretase. This increases processing at these sites and is revealed by the cellular assay. Once enriched cells are obtained by FACS, the DNA encoding the random peptide is recovered from the cells by PCR amplification and  
20 recloned into the peptide library expression vector. These are procedures known to someone trained in this art. The isolated clones are amplified in bacteria, repackaged in the retroviral packing cells, used to infect naive assay cells, and the enrichment process is repeated until clones encoding true effector peptides are obtained. DNA sequence analysis of the clones encoding the random peptide sequence reveals the sequence of the effector  
25 peptide.

Once one or more effector peptides have been identified, the effector peptides can be tested for their ability to effect the structure of APP. Methods for testing or analyzing the binding of the effector peptides are well known and include methods described above for prescreening peptide libraries.

30

Example 10: Characterization of Effector Peptide

The effector peptide is characterized to show that soluble A $\beta$  is reduced in cultures under the influence of the effector peptide. ELISA and Western blot analysis of culture medium from assay cells plus and minus expression of effector peptide can be used  
5 to verify the desired effect.

In one assay, an effector peptide that increase  $\alpha$ -secretase processing of APP (herein "EM $\alpha$  peptide") is coexpressed with human APP in HEK293 cells or SH-SY5Y cells. The expression level of full length APP is determined in the presence or absence of the effector peptide by Western blot analysis (antibody 6E10 or 22C11).  
10 Furthermore, efficacy testing of the effector peptide assesses its capacity to reduce protofibrils and monomeric soluble A $\beta$ 1-40 and A $\beta$ 1-42 levels in the media after peptide expression. Levels of A $\beta$  protofibrils and A $\beta$ 1-40/42 is determined by ELISA, using different antibodies. The commercially available antibodies (*i.e.*, Biosource/QCB cat # 44-348 and 44-344) are used to specifically quantitate A $\beta$ 40 and A $\beta$ 42, respectively.

15 Similarly, the effect of peptides that decrease  $\beta$ -secretase processing of APP (herein "EM $\beta$  peptide") on the expression level of APP and A $\beta$ 40 and A $\beta$ 42 is characterized in a similar manner.

The effect of EM $\alpha$  and EM $\beta$  peptides on nearby processing activities is also characterized. In cells expressing an EM $\alpha$  peptide, the release of APPs $\beta$ , APPs $\gamma$  and  
20 as well as the C-terminal fragments CT99, is compared to the release of these fragments when the EM $\alpha$  peptide is not expressed. A different fragment pattern indicates interference. In analogy, the release of APPs $\alpha$ , APPs $\gamma$ , p3, and CT 57/59 is determined with and without expression of the EM $\beta$  peptide.

Whether the specificity or efficacy of an EM $\alpha$  or EM $\beta$  peptide is altered in  
25 familial AD mutations is also determined. The following APP mutations are used for this study:

(a) Swedish (Lys670Asn; Met671Leu), 2 amino acids N-terminally to the  $\beta$ -cleavage site;

(b) Flemish (Ala692Gly), 5 amino acids C-terminally to the  $\alpha$ -cleavage  
30 site;

- (c) Dutch (Glu693Gln), 6 amino acids C-terminally to the  $\alpha$ -cleavage site;
- (d) Arctic (Glu693Gly), 6 amino acids C-terminally to the  $\alpha$ -cleavage site;  
and
- (e) Iowa (Asp694Asn), 7 amino acids C-terminally to the  $\alpha$ -cleavage site.

5           Also assessed is whether an APP mutation affects the affinity or association kinetics of an EM $\alpha$  or EM $\beta$  peptide to the APP protein and APP processing rates. Binding studies are performed by incubating a radiolabelled EM $\alpha$  or EM $\beta$  peptide with HEK293 cells expressing wild-type APP or mutated forms of APP.

10           Processing at the  $\beta$ -site is significantly increased when APP contains the Swedish mutation. (See Mullan *et al.*, *Nat. Genet.* 1:345-347, 1992.) For example, in transgenic mice expressing human APP with the Swedish mutation (hamster prion promoter-hAPP<sub>Swe</sub>), SDS soluble A $\beta$ 40 and A $\beta$ 42 peptides are increased from 21 and 6 pmol/g at 5 months of age to 11,100 and 2,000 pmol/g at 21 months, respectively. (Kawarabayashi *et al.*, *J. Neurosci.* 15:372-381, 2001). Co-transfection of an EM $\beta$   
15 peptide with APP<sub>Swe</sub> indicates whether the Swedish mutation affects the EM $\beta$  peptide's inhibitory action on the  $\beta$ -site cleavage or not. Similarly, also assessed are the effects of APP mutations (b)-(e) near the  $\alpha$ -site, see supra, on EM $\alpha$  peptide-stimulated  $\alpha$ -cleavage.

20           The efficacy of an effector peptide (EP) in reducing the amount of A $\beta$  can also be assessed in a suitable transgenic animal model that over expresses A $\beta$ , for example Tg(HuAPP695.K670N/M671L)2567 or PDAPP. (See also, e.g., Examples 11 and 12, *infra.*)

25           Additional characterization involves identification of the target of the peptide. These assays utilize the display complex (presentation protein with tethered peptide) as well as the peptide alone as affinity labels. Binding of the peptide to APP is assessed by labeling the peptide and assessing binding to the extracellular domain of APP. Fluorescent labeled peptide is also used to assess binding to the assay cells expressing APP, with a comparison to control assay cells not expressing APP.

30           To assess binding to processing enzymes, labeled peptide is used to determine peptide binding to parental assay cells and comparing peptide binding to cells known to not express the processing enzymes. Additional characterization can comprise

labeled peptide mixed with solubilized cell lysates and fractionated by ion exchange and size exclusion chromatography, 2-D electrophoresis, and mass spectrum analysis of protein spots to determine binding to other cell components. It is possible that an effector peptide binds and alters the function of another cellular molecule causing a reduction in A $\beta$  without binding to APP or without altering the processing of other important biological molecules.

Example 11: *In Vivo* Efficacy Testing of Effectors of APP Processing in Transgenic Mice - Direct Peptide Administration

*In vivo* efficacy testing of an EM $\alpha$  peptide will assess its capacity to stimulate APP $\alpha$ -secretase cleavage rates and lowering of A $\beta$  protofibrils and A $\beta$ 40/42 levels in the brain. Protofibril levels and brain distribution are assayed by ELISA and immunohistochemistry using a protofibril-specific monoclonal antibody. Plaque burden is determined using standard procedures involving perfusion and fixation of brain tissue in 4% paraformaldehyde and immunostaining with A $\beta$ -antibody (*e.g.*, with 6E10 as previously described (*see Nilsson et al., J. Neurosci., 21:1444-1451 2001*)).

Initial testing of EM $\alpha$  and EM $\beta$  peptides involves direct administration of the peptide by subcutaneous or intraperitoneal injections to Tg mice for measuring blood-brain-barrier passage properties. Passage is assessed by determination of the EM $\alpha$  or EM $\beta$  peptide in CSF and brain homogenate after brain perfusion using an anti-EM $\alpha$  or anti-EM $\beta$  peptide ELISA method, respectively. Different dose levels are tested and correlated to peptide levels obtainable in brain and CSF. *In vitro* experiments provide information on the concentrations of the EM $\alpha$  or EM $\beta$  peptide required to obtain significant stimulation of  $\alpha$ -secretase or inhibition of  $\beta$ -secretase, respectively. An alternative and more sensitive approach is to radiolabel (iodinate) the peptides and determine their radioactivity in CSF and brain homogenate. Although this method is more sensitive, it can give erroneous results due to modification of the peptide. Furthermore, half-life for the EM $\alpha$  or EM $\beta$  peptide is determined in CSF, brain, and serum using standard procedures, as a guidance for dosing frequency in the animal efficacy studies. A constant CSF/brain concentration of the EM $\alpha$  or EM $\beta$  peptide over time is typically desired. If the EM $\alpha$  or EM $\beta$  peptide shows satisfactory passage properties, then efficacy testing is performed. However, if passage properties of the EM $\alpha$  or EM $\beta$  peptide are not

satisfactory, then efficacy testing by direct subcutaneous or intraperitoneal administration of the peptides is not be performed. An alternative approach is to deliver the peptides by i.c.v. using an osmotic pump (Alzet) or to directly express the peptide in the brain of Tg mice (*see infra*).

5 In one study, efficacy testing of the EM $\alpha$  or EM $\beta$  peptide is by direct peptide administration. Efficacy testing by direct administrations involves administration of the EM $\alpha$  or EM $\beta$  peptide for 4-6 months to Tg mice, with reduction of A $\beta$ 40/42 and A $\beta$  protofibril levels as an endpoint. A reduction of A $\beta$  levels likely leads to a reduction of A $\beta$  protofibrils, since formation of protofibrils are dependent on A $\beta$ 1-40 and A $\beta$ 1-42  
10 concentrations. A suitable mouse strain is mThy1-hAPP<sub>Swe</sub>, which carries a transgene coding for the 695-amino acid isoform of human Amyloid Precursor Protein (APP) containing the Swedish mutation which is an ongoing project in our laboratory and similar to a well-established AD model (*see Hsiao et al., Science 274:99-102, 1996*). Thus, the mThy1-hAPP<sub>Swe</sub> likely shows a significant time-dependent increase of A $\beta$ 1-40 and A $\beta$ 1-  
15 42, large amyloid depositions, aged-correlated elevation of brain cholesterol and ApoE, as well as altered synaptic efficacy (*see Kawarabayashi et al., J. Neurosci. 15:372-381, 2001*). This “Hsiao-APP mouse” model has also been shown to develop behavioral deficits (*see Westerman et al., J. Neurosci. 22:1858-1867, 2002*).

Efficacy testing is also performed in a double transgenic model (mThy1-  
20 hAPP<sub>SweArc</sub>), containing both the Swedish and Arctic mutation. This model is developed to establish a model that produces high levels of A $\beta$ Arc protofibrils in the brain. A $\beta$  protofibrils are neurotoxic (*see Hartley et al., J. Neurosci. 19:8876-8884, 1999*) and affects early synaptic function (*see Selkoe, Science 298:789-791, 2002*). Nilsberth *et al.* (*Nat. Neurosci. 4:887-893, 2001*) has shown that the Arctic mutation confers higher  
25 protofibril stability and rate of formation, leading to early onset of AD.

Short-term administration (2-3weeks) of the EM $\alpha$  or EM $\beta$  peptide at an early age, prior to any amyloid deposition and when the A $\beta$  levels shows little age-dependent increase, assesses their mechanistic ability to alter APP processing *in vivo*. Further, the prophylactic effect of the EM $\alpha$  or EM $\beta$  peptide is evaluated in young Tg mice  
30 by long-term administration starting prior to the onset of amyloid deposition and continuing until a time point when the transgenic mouse model is known to display robust amyloid deposition. Finally, the therapeutic efficacy of the EM $\alpha$  or EM $\beta$  peptide is

examined by long-term administration to old mice after the onset of amyloid deposition. Various measures of amyloid pathology are determined to assess the efficacy and safety (e.g., A $\beta$  and Thioflavine S plaque burden, extractable A $\beta$ 1-40 and A $\beta$ 1-42, A $\beta$  protofibrils as assessed by sequential extraction (TBS, Triton X-100, SDS and formic acid), and ELISA). Secondary tissue damage such as neurodegenerative changes (neuritic dystrophy, synaptic loss, oxidative damage) is also analyzed preferentially with immunohistochemistry and quantitative image analysis. Traditional markers of cerebral inflammation such as GFAP (astrogliosis) and MAC-1/CD11 and IL-1 (microgliosis) are determined, as well as other pro-inflammatory cytokines such as  $\gamma$ -IFN, IL-2, and IL-6 and anti-inflammatory cytokines such as TGF- $\alpha$ , IL-4, and IL-10. Prevention of cognitive dysfunction is studied in the Radial Arm Water Maze, which is more sensitive to “episodic-like” memory than the classical Morris Water Maze.

Example 12: *In Vivo* Efficacy Testing of Effectors of APP Processing in Transgenic Mice - Peptide Expression *In Vivo*

15                   If the blood-brain-barrier passage properties of the EM $\alpha$  or EM $\beta$  peptide are not satisfactory, an alternative strategy for efficacy testing is performed by direct *in vivo* expression of the effector peptide in brains of transgenic mice. Two different expression vector constructs are generated, both in which an EM $\alpha$  or EM $\beta$  peptide coding sequence is expressed in neurons using, e.g., the Thy-1 promoter. One DNA construct (herein Thy1-Em $\alpha$ /EM $\beta$ <sub>S</sub>) is engineered so that the effector peptide is expressed in a secreted (S) form in the brain; the other DNA construct (herein Thy1-Em $\alpha$ /EM $\beta$ <sub>M</sub>) contains a GPI-linker and thereby targets the expressed peptide to neuronal membranes (M). (See Figure 8.) Thy1-Em $\alpha$ /EM $\beta$ <sub>S</sub> and Thy1-Em $\alpha$ /EM $\beta$ <sub>M</sub> transgenic mice are then generated using standard procedures.

25                   Thy1-Em $\alpha$ /EM $\beta$ <sub>S</sub> and Thy1-Em $\alpha$ /EM $\beta$ <sub>M</sub> transgenic mice are crossed with Thy1-hAPP<sub>Swe</sub> and mThy1-hAPP<sub>SweArc</sub> transgenic mice to determine the efficacy of the EM $\alpha$  or EM $\beta$  peptide *in vivo*. These multiple transgenic models are also used to characterized effect of the peptide on compartmentalization of APP processing. The effect of secreted or membrane-bound (e.g., ER-, Golgi-, plasma membrane-bound) EM $\alpha$  peptide on APP $\alpha$ -secretase cleavage rates are determined. Similarly, the effect of secreted or membrane-bound EM $\beta$  peptide on  $\beta$ -secretase cleavage rates are also examined. These

studies provide important *in vivo* data, such as, *e.g.*, whether increased  $\alpha$ -site processing or decreased  $\beta$ -site processing translates into a reduction in A $\beta$  protofibril and A $\beta$ 40/42 levels, less amyloid depositions, less inflammation and/or improved cognitive functions.

5 The previous examples are provided to illustrate, but not to limit, the scope of the claimed inventions. Other variants of the inventions will be readily apparent to those of ordinary skill in the art and encompassed by the appended claims. All publications, patents, patent applications and other references cited herein and are also incorporated by reference herein in their entirety.

WHAT IS CLAIMED IS:

1. A method for identifying an agent that alters processing of a membrane protein of interest, comprising:

contacting the agent with an animal host cell that expresses the membrane protein and at least one processing enzyme of the membrane protein, and

5 detecting altered processing of the membrane protein to identify the agent that alters the processing of the membrane protein

2. The method of claim 1, wherein detecting the altered membrane protein processing comprises assessing the relative presence or absence of at least one species of membrane protein fragment on the surface of the host cell or released from the surface of the host cell.

3. The method of claim 2, wherein the at least one species of membrane protein fragment is released from the surface of the host cell.

15

4. The method of claim 1, wherein the at least one membrane protein processing enzyme is a protease or a phospholipase.

5. The method of claim 1, wherein the altered membrane protein processing results in a decreased production of a fragment of the membrane protein released from the cell surface.

20

6. The method of claim 5, wherein the released fragment is associated with an increased risk of disease.

25

7. The method of claim 6, wherein the disease is an inflammatory disease, cancer, diabetes, Alzheimer's disease, or Parkinson's disease.

8. The method of claim 1, wherein the agent is from a compound library.

30

9. The method of claim 8, wherein the compound library is a combinatorial chemical library.
10. The method of claim 8, wherein the compound library is a natural products library.
- 5 11. The method of claim 8, wherein the compound library is a peptide library.
12. The method of claim 1, wherein the agent is a small molecule.
13. The method of claim 1, wherein the agent is a biomolecule.
14. The method of claim 13, wherein the biomolecule is a peptide.
- 10 15. The method of claim 14, wherein the peptide is produced by transcription and translation from an oligonucleotide encoding the peptide.
16. The method of claim 15, wherein the oligonucleotide has a length of about 18 to about 120 nucleotides.
17. The method of claim 15, wherein the oligonucleotide has a length of  
15 about 36 to about 60 nucleotides.
18. The method of claim 15, wherein contacting the peptide with the host cell comprises introducing an expression vector, the expression vector comprising the oligonucleotide encoding the peptide, into the host cell, the host cell thereby expressing and displaying the peptide within a secretory pathway and on an extracellular cell surface.
- 20 19. The method of claim 15, wherein the oligonucleotide is from an expression library comprising a plurality of oligonucleotides, at least of majority of the oligonucleotides having different sequences encoding a different peptide.
20. The method of claim 19, wherein the sequence of the plurality of oligonucleotides is randomized.
- 25 21. The method of claim 19, wherein the expression library is pre-

enriched for oligonucleotides encoding peptides that specifically bind to the membrane protein.

22. The method of claim 19, wherein the contacting of the peptide with the host cell comprises introducing the expression library into a first plurality of animal  
5 host cells that express the membrane protein and at least one processing enzyme of the membrane protein, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface.

23. The method of claim 22, further comprising:

selecting from the first plurality of host cells displaying the different  
10 peptides a first subset of host cells that exhibit altered membrane protein processing; and

identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of the membrane protein.

24. The method of claim 22, wherein the first plurality of host cells  
15 displaying the different peptides have been enriched using a selectable marker.

25. The method of claim 24, wherein the selectable marker is V5, FLAG, or thioredoxin.

26. The method of claim 24, wherein the enrichment comprises magnetic bead selection.

20 27. The method of claim 24, wherein the enrichment comprises selection by fluorescence-activated cell sorting.

28. The method of claim 24, wherein the host cells expressing and displaying the different peptides on the extracellular cell surface express a high copy number of the different peptides.

25 29. The method of claim 15, wherein the peptide is displayed as a fusion protein with a presentation molecule.

30. The method of claim 29, wherein the presentation molecule is CD24.
31. The method of claim 29, wherein the presentation molecule is IL-3 receptor.
- 5 32. The method of claim 29, wherein the presentation molecule is thioredoxin.
33. The method of claim 29, wherein the fusion protein further comprises a marker epitope.
34. The method of claim 33, wherein the marker epitope is  
10 polyhistidine, V5, FLAG, or myc
35. The method of claim 29, wherein the fusion protein further includes a signal for a glycosphosphatidylinositol (GPI) anchorage.
36. The method of claim 1, wherein the animal host cell is a mammalian host cell.
- 15 37. The method of claim 1, wherein the animal host cell is a recombinant host cell.
38. The method of claim 37, wherein the animal host cell is an isolated cell.
39. The method of claim 1, wherein the agent is contacted with the host  
20 cell under substantially physiological conditions.
40. The method of claim 39, wherein the substantially physiological conditions comprise the presence of a complex biological fluid.
41. The method of claim 40, wherein the complex biological fluid is blood, serum, plasma, or cerebral spinal fluid (CSF).
- 25 42. The method of claim 2, wherein the assessment of the relative

presence or absence of at least one species of a membrane protein fragment on the cell surface comprises contacting the host cell with at least one detectably labeled marker that specifically binds to the at least one species of membrane fragment and detecting the bound, labeled marker.

5                   43.     The method of claim 42, wherein the at least one marker is an antibody that binds to a predetermined epitope of the membrane protein or a membrane protein fragment.

                  44.     The method of claim 43, wherein the assessment of the relative presence or absence of at least one species of membrane protein fragment on the cell  
10     surface further comprises determining a ratio of the detection signals of at least two labeled antibodies specific for at least two different epitopes of the membrane protein or a membrane protein fragment.

                  45.     The method of claim 1, wherein the agent is an allosteric effector of the membrane protein.

15                   46.     The method of claim 1, wherein the detecting altered processing of the membrane protein on the surface of the host cell comprises the use of a flow sorter.

                  47.     A method for identifying a peptide that alters processing of an angiotensin converting enzyme (ACE) membrane protein comprising:

                  introducing an expression library comprising a plurality of  
20     oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE membrane protein and at least one ACE processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface;

25                   selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing; and

                  identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that

alters the processing of ACE.

48. The method of claim 47, wherein the animal host cell is a mammalian host cell.

49. The method of claim 47, wherein the animal host cell is a  
5 recombinant host cell.

50. The method of claim 47, wherein the animal host cell is an isolated cell.

51. The method of claim 47, wherein the first plurality of host cells display the different peptides under substantially physiological conditions.

10 52. A method for identifying a peptide that alters processing of ACE membrane protein comprising:

pre-enriching an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, for at least one oligonucleotide that encodes a peptide that  
15 specifically binds to ACE, the pre-enrichment comprising the steps of

introducing the expression library into a phage display vector which can express the peptides encoded by the oligonucleotide sequences on the surface of the phage;

20 expressing the different peptides on the surface of the phage;

selecting a subset of phage particles that express peptides that specifically bind ACE membrane protein;

recovering the oligonucleotide sequences from the selected phage particles to form a pre-enriched expression library

25 introducing the pre-enriched expression library into a first plurality of animal host cells that express ACE membrane protein and at least one ACE membrane protein processing enzyme, the host cells thereby expressing and displaying the at least one ACE-binding peptide within a secretory pathway and on an extracellular cell surface;

selecting from the first plurality of host cells displaying the at least one ACE membrane protein-binding peptide a first subset of host cells that exhibit altered ACE processing; and

5 identifying from the first subset of host cells a first sub-library of the pre-enriched expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE.

53. A method for identifying a peptide that alters processing of ACE membrane protein comprising:

10 introducing an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE membrane protein and at least one ACE membrane protein processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface;

15 selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing; wherein the altered ACE processing is determined by assessing the relative presence or absence of at least one species of ACE released from the surface of the host cells displaying the different peptides by contacting the host cells with at least one detectably labeled marker  
20 that specifically binds to the at least one species of ACE fragment and detecting the bound labeled marker; and

identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE membrane protein.

25 54. A method for identifying a peptide that alters processing of ACE membrane protein comprising:

introducing an expression library comprising a plurality of oligonucleotides, at least a majority of the oligonucleotides having different sequences encoding different peptides, into a first plurality of animal host cells that express ACE

membrane protein and at least one ACE processing enzyme, the host cells thereby expressing and displaying the different peptides within a secretory pathway and on an extracellular cell surface under substantially physiological conditions;

- 5 selecting from the first plurality of host cells displaying the different peptides a first subset of host cells that exhibit altered ACE processing; wherein the altered ACE processing is determined by assessing the relative presence or absence of at least one species of ACE fragment on the surface or released from the surface of the host cells displaying the different peptides by contacting the host cells with at least one detectably labeled marker that specifically binds to the at least one species of ACE
- 10 fragment and detecting the bound labeled marker; and

identifying from the first subset of host cells a first sub-library of the expression library comprising at least one oligonucleotide that encodes the peptide that alters the processing of ACE membrane protein.

Figure 1.

**The amyloid cascade  
leading to Alzheimer's disease**




Figure 2.




Figure 3.




Figure 4.




Figure 5.






Figure 7





Figure 8



## SEQUENCE LISTING

<110> ICOGEN CORPORATION

<120> METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING OF A MEMBRANE BOUND PRECURSOR PROTEIN

<130> 17881-11-1PC

<140> PCT/US03/35289

<141> 2003-11-04

<150> US 60/424,030

<151> 2002-11-04

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Xpress™ leader peptide

<400> 1

Asp Leu Tyr Asp Asp Asp Asp Lys  
1 5

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> a myc epitope

<400> 2

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn  
1 5 10

<210> 3

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> V5 epitope

<400> 3

Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr  
1 5 10

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> FLAG tag

<400> 4

Asp Tyr Lys Asp Asp Asp Asp Lys  
1 5

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Factor Xa restriction cleavage amino acid sequence

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223>

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> X=any amino acid

<400> 5

Ile Glu Gly Arg Xaa  
1 5

User: pics8  
Host: pgpubt50  
Class:  
Job: pois\_8-240

专利名称(译)	用于鉴定调节膜结合前体蛋白的结构和加工的试剂的方法		
公开(公告)号	<a href="#">EP1563067A2</a>	公开(公告)日	2005-08-17
申请号	EP2003781766	申请日	2003-11-04
[标]申请(专利权)人(译)	ICOGENEX CORP		
申请(专利权)人(译)	ICOGENEX CORPORATION		
当前申请(专利权)人(译)	ICOGENEX CORPORATION		
[标]发明人	HAGEN FREDERICK S		
发明人	HAGEN, FREDERICK S.,		
IPC分类号	A61K49/00 C12N15/00 C12Q G01N33/53 G01N33/567 G01N33/68		
CPC分类号	C12Q1/34 G01N33/566 G01N33/6896 G01N2333/948 G01N2500/10		
优先权	60/424030 2002-11-04 US		
其他公开文献	EP1563067A4		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明提供了从大的分子结构文库中筛选和鉴定试剂的方法，所述分子结构可以改变目的膜蛋白的裂解。通过本发明方法鉴定的修饰膜蛋白裂解的试剂可用于治疗和预防疾病，例如炎症，糖尿病，癌症，阿尔茨海默病，帕金森氏病等。该方法选择并鉴定与目的膜蛋白结合的效应剂，引起膜蛋白结构的变化，从而调节分泌酶裂解的效率。此外，该方法在体内系统中进行，该系统提供与膜蛋白加工条件相似或相同的生理条件。可以选择试剂的能力导致膜蛋白的分泌酶切割减少或增加。